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Abstract
Two reasons for subpar coverage of the Human papillomavirus (HPV) vaccine are missed
clinical opportunities and nonacceptance of the vaccine upon recommendation from a medical
provider. The purpose of study one was to examine factors associated with access and adherence
to physician’s recommendations in association with HPV vaccine uptake. Data were obtained
from National Health Interview Survey (2017). Variables theoretically related to clinical
opportunities and adherence to physician’s recommendations were examined in association with
HPV vaccine uptake. Univariate logistic regressions were run to determine the associations
between the aforementioned variables and uptake of the HPV vaccine. Multinomial logistic
regressions were used to determine if the variables demonstrate different associations between
those who received the vaccine between 9-16 years of age and 17-26 years of age, compared to
never receiving the vaccine. The sample was limited to females aged 18-26 years. Compared to
receiving no health care, receiving care from a general medical provider (GP) only was
associated with higher vaccine uptake; however, there no difference in respondents who received
care from an OBGYN only and respondents who saw an OBGYN and a GP had the highest
vaccine uptake. These same patterns of association were present in the multinomial model for
those who received the vaccine between 9-16 years of age, but not 17-18 years of age. No other
variables were associated with the uptake of the HPV vaccine in either the logistic or
multinomial regression models. Seeing a GP, but not an OBGYN is associated with greater
protection from HPV infections. Engaging in routine and preventative measures at a younger age
may result in continuing this behavior into young adulthood. In the past two decades cancer was
acknowledged as a new health concern for individuals with an intellectual disability (ID).
Despite such recognition, no research in the US has sought to examine their uptake of the cancer-

preventing, HPV vaccine. Physicians can provide insight into the factors they consider when
deciding whether to recommend the vaccine and can provide insight into the discussions they
have with patients/caregivers regarding the vaccine. The purpose of this study was to examine
physicians’ experiences of recommending the HPV vaccine to females with an ID. An online
open-ended survey was employed. Data were analyzed using inductive content analysis. Fortynine out of 51 participants had previously recommended the HPV vaccine to females with an ID.
Physicians believed the HPV vaccine was important because of the population’s noncompliance
with pap smears and risk of sexual abuse. Physicians believed the vaccine was less important for
patients who were unlikely to be sexually active. Physicians generally described parents as
uncertain, but receptive of the vaccine. There were some responses which implied caregivers did
not believe their child would be sexually active and therefore were not at risk for contracting
HPV. Both patients and parents believed immunizations generally could be traumatic for this
population. Physicians were supportive of the HPV vaccine for females with an ID and perceived
parents as wanting to protect their child, but uncertain about the vaccine’s necessity.
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Introduction
Human papillomavirus (HPV) is spread through sexual contact and is pervasive amongst
sexually active adults (National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention,
2019). Each year 14 million people become newly infected with HPV (Center for Disease
Control and Prevention, 2017). Although there are many serotypes of HPV, 14 are considered
high risk for cancer or genital warts (American College of Obstetrics and Gynecology, 2017;
National Institutes of Health, 2010). HPV is responsible for nearly all cases of cervical cancer,
90% of anal cancers, 70% of oropharyngeal cancers, 65% of vaginal cancers, and 50% of all
vulvar cancers (Centers for Disease Control and Prevention, 2018a). Consequently, HPV
contributes to over 30,000 new cancer cases each year (Centers for Disease Control and
Prevention, 2018a).
A vaccine to prevent the high-risk serotypes of HPV was approved in 2006 (Centers for
Disease Control and Prevention, 2018b). The current recommended schedule for the HPV
vaccine suggests administration to all children 11-12 years of age (Centers for Disease Control
and Prevention, 2018b; Meites et al., 2016). For those who do not receive the vaccine as a
preteen, there is a catch-up vaccine schedule targeting persons aged 26 years and younger
(Centers for Disease Control and Prevention, 2018b; Centers for Disease Control and
Prevention., 2018c). If the HPV vaccine series is initiated before 14 years of age, two doses of
the vaccine are recommended, and if initiated after the age of 14, three doses are recommended
(Centers for Disease Control and Prevention, 2018b). As of August 2019, the CDC released an
updated HPV vaccine recommendation. The new guidelines indicate that the HPV vaccine can
be administered to adults aged 27-45 years of age. However, the benefit of doing so is minimal
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because of the high likelihood of past exposure to HPV, which reduces the effectiveness of the
vaccine (Meites et al., 2019).
Despite a national health priority dedicated to increasing the prevalence of adolescents
who receive the HPV vaccine to 80% by 2020, estimates indicate that roughly half of all female
adolescents are currently vaccinated (Healthy People, 2014; Walker et al., 2017). The President’s
Cancer Panels (2013) identified three reasons for suboptimal uptake: missed clinical
opportunities, low acceptance of the HPV vaccine by parents and patients, and accessibility of
the vaccine. Missed clinical opportunities are the number one reason for low HPV vaccine
coverage in the United States (President’s Cancer Panel, 2013). In females, wellness visits with a
medical provider are routine until the age of 16 (Rand & Goldstein, 2018) and they typically
include consultation about risk factors for cancer such as tobacco use, but often fail to discuss
HPV (President’s Cancer Panel, 2013; Stokley, 2011). The failure to discuss the HPV vaccine is
a missed clinical opportunity because a strong recommendation from a physician is a significant
predictor of receiving the HPV vaccine (Rosenthal et al., 2011). On the most basic level,
physically visiting a health care provider is required to receive recommendations regarding care.
The prevalence of receiving routine wellness visits becomes infrequent after the age of 16 (Rand
& Goldstein, 2018), meaning adolescents who do not receive the HPV vaccine before the age of
16 may have fewer opportunities to receive a recommendation to obtain the HPV vaccine. There
is an additional barrier for women to receive the HPV vaccine after the age of 16. Physicians
report that patients are approximately 17 years of age when they begin to present themselves at
medical appointments without the supervision of a parent or legal guardian (Ford et al., 2014). A
17-year-old cannot consent to receive the HPV vaccine without a parent or legal guardian
(National Conference of State Legislatures, 2018) and between 30%-50% of physicians indicated
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they would not vaccinate a 17-year-old at their clinic with their parent’s consent (Ford et al.,
2014). As such, adolescents who do not receive the vaccine prior to 16 years of age may have to
wait until after they turn 18 years of age to receive the vaccine. As the average age of first sex in
the United States is around 17 years of age, this is problematic for the prevention of HPV
infections (Planned Parenthood, 2011).
Typically, the literature in the United States has focused on three primary care specialties
pediatricians, gynecologists, and family practitioners. Those ignored in the current body of
literature on the HPV vaccine are complementary and alternative medicine (CAM) providers. In
recent years, the use of CAM care has increased in the United States, and 4 out of 10 adults have
sought this type of care (National Center for Complementary and Integrative Health, 2017).
Examples of CAM include naturopathic and homeopathic medicine (National Center for
Complementary and Integrative Health, 2017). Naturopathic and homeopathic practitioners often
propagate rhetoric consistent with vaccine-hesitant culture (Caulfield et al., 2017), which may
elucidate why consumers of CAM report a fear of vaccines and reject their use (Tissot et al.,
2007). Consequently, children who have seen a CAM provider are four times less likely to
receive the influenza vaccine compared to children who have never seen a CAM provider (Bleser
et al., 2016; Salmon et al., 2005). However, it is unknown if there is an association between
CAM utilization and receiving the HPV vaccine.
Once the physician provides a recommendation to receive the HPV vaccine, the patients
need to adhere to their physician’s recommendation. There is a robust body of literature
examining factors associated with increased patient adherence to physicians’ recommendations.
For example, the following are all linked to increased patient adherence: physicians using
language that is comprehensible (Martin et al., 2005), physicians respecting or sharing the
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patient’s culture, values, beliefs or opinions (Newell & Jordan, 2015; Ohana & Mash, 2015), and
patient satisfaction with health care (Bogart et al., 2004; Taylor et al., 2016). Nevertheless, none
of these factors have been examined in association with the HPV vaccine uptake.
The first purpose of this study was to examine women’s health care utilization in the past
12 months in association with their HPV vaccine uptake. For women who received health care in
the previous 12 months, characteristics of their patient-provider relationship (that have been
previously associated with adherence to physician’s recommendation) were examined in
association with their HPV vaccine uptake. Additionally, women’s health care utilization was
examined to determine if the associations differed between females who received the HPV
vaccine during the FDA approved age range but before the national average age of sexual debut
(9-16 years) or after the national average age of sexual debut (Planned Parenthood, 2011), but
within the FDA approved age range for the year 2017 (17-26 years) compared to a referent group
of females who never received the HPV vaccine. Finally, characteristics of the health care they
received were examined specifically in those who received the HPV vaccine between 17-26
years of age, when they theoretically had more agency in their health care decisions (Ford et al.,
2014).
As previously mentioned, parents’ or patients’ lack of acceptance of the HPV vaccine, is
one reason for subpar coverage in the United States (President’s Cancer Panels, 2013). There is a
large body of literature dedicated to the parental acceptance of the HPV vaccine for their child.
Although the vaccine can now be administered through the age of 45, the youngest age at which
it can be administered is nine years (Centers for Disease Control and Prevention, 2018b; Meites
et al., 2019). Therefore, there are several years in which parents or caregivers are the gatekeepers
between physicians recommending the vaccine and children receiving the vaccine.
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Parental hesitation to accept the HPV vaccine when recommended often stems from their
perception of their child(ren) as not being sexually active (Javaid et al., 2017; Perkins et al.,
2014) and therefore assume their children are not at risk for sexually transmitted infections (STI)
(Hughes et al., 2011). While parents who foresee their children becoming sexually active in the
future (and therefore at risk for contracting HPV) are more likely to accept the vaccine for their
children (Barnack et al., 2010; Brewer & Fazekas, 2007). Furthermore, even though parents were
cognizant that they likely would be unaware of their child’s sexual debut (Perkins et al., 2014),
they were afraid their child would have an earlier sexual debut or engage in riskier sexual
behaviors if the HPV vaccine were administered to them (Brewer & Fazekas, 2007; Daley et al.,
2010).
For females with an intellectual disability (ID), parental acceptance of the HPV vaccine
may be an even greater boundary to vaccine initiation. There is a lack of sexuality education
curricula explicitly designed for this population (Murphy et al., 2006). Women with an ID may
not be able to or may not know it is important to advocate for themselves to receive the vaccine
because safe sex practices regarding STIs and sexual health knowledge are poor in this
population (Bernert & Ogletree, 2013; Servais, 2006).
Additionally, females with an ID who lack decisional capacity will require a parent or
legal guardian’s consent regarding health care decisions throughout their life span (National
Council on Disability, 2019), consequently emphasizing parental acceptance to an even greater
extent. However, to date, there is no data examining parents’ or legal guardians’ acceptance of
the HPV vaccine for female children with an ID.
Parents of children with an ID often view their children as asexual and unlikely to engage
in sexual behaviors (Stein & Kohut, 2015), which may mean parental acceptance of the HPV
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vaccine for their children is even more challenging in this population than the typicallydeveloping population. These parents deny the potential for their children to engage in partnered
sexual activity because their children struggle to form social connections with their peers
(Ballan, 2012). Other parents of children with an ID recognized that their children have sexual
desires and sexual urges but were primarily concerned about their children acting on their sexual
urges in a manner that was outside the scope of accepted social norms (Rehm, Fuentes-Afflick,
Fisher, & Chesla, 2012). In another study, parents of children with an ID reported concerns for
their children becoming victims of sexual exploitation (Ballan, 2012), Notably, respondents
never mentioned STIs to be of concern suggesting that they may not recognize the threat of HPV
on their child’s long-term health. Parents’ perceptions of their children with an ID may
inadvertently contribute to missed clinical opportunities to receive the HPV vaccine in this
population as well.
First, physicians have less motivation to recommend the HPV vaccine to parents whom
they anticipate will refuse (Kepka et al., 2012). Parents sometimes refuse the vaccine because
they do not believe their child is sexually active (Hughes et al., 2012) and the literature
demonstrates, some parents of children with ID do not see their child as sexually active (Stein &
Kohut, 2015). Secondly, providers sometimes recommend the HPV vaccine based on their
estimation of the patient’s engagement in sexual activity (Kepka et al., 2012; Perkins et al.,
2014). Although there is no evidence to conclusively say physicians perceive females with an ID
as asexual, a review study concluded that women with an ID are inaccurately viewed as asexual
(Milligan & Neufeldt, 2001), suggesting physicians may hold similar views.
Therefore, the second purpose of this study was to explore the physician's experiences of
recommending the HPV vaccine to parents or caregivers of female children with an ID and their
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reasons for recommending or not recommending the HPV vaccine to female patients with an ID.
Secondly to parents or caregivers have after receiving a recommendation for their female child
with an ID to receive the HPV vaccine.

7

References
American College of Obstetrics and Gynecology. (2017). Human Papillomavrius (HPV) vaccine
(Frequently Asked Question Women’s Health No. faq191).
Barnack, J. L., Reddy, D. M., & Swain, C. (2010). Predictors of parents’ willingness to vaccinate
for human papillomavirus and physicians’ intentions to recommend the vaccine.
Women’s Health Issues, 20(1), 28–34. https://doi.org/10.1016/j.whi.2009.08.007
Bernert, D. J., & Ogletree, R. J. (2013). Women with intellectual disabilities talk about their
perceptions of sex. Journal of Intellectual Disability Research, 57(3), 240–249.
https://doi.org/10.1111/j.1365-2788.2011.01529.x
Bleser, W. K., Elewonibi, B. R., Miranda, P. Y., & BeLue, R. (2016). Complementary and
alternative medicine and Influenza vaccine uptake in US children. Pediatrics, 138(5),
e20154664. https://doi.org/10.1542/peds.2015-4664
Bogart, L. M., Bird, S. T., Walt, L. C., Delahanty, D. L., & Figler, J. L. (2004). Association of
stereotypes about physicians to health care satisfaction, help-seeking behavior, and
adherence to treatment. Social Science & Medicine, 58(6), 1049–1058.
https://doi.org/10.1016/S0277-9536(03)00277-6
Brewer, N. T., & Fazekas, K. I. (2007). Predictors of HPV vaccine acceptability: A theoryinformed, systematic review. Preventive Medicine, 45(2–3), 107–114.
https://doi.org/10.1016/j.ypmed.2007.05.013
Caulfield, T., Marcon, A. R., & Murdoch, B. (2017). Injecting doubt: Responding to the
naturopathic anti-vaccination rhetoric. Journal of Law and the Biosciences, 4(2), 229–
249. https://doi.org/10.1093/jlb/lsx017
Center for Disease Control and Prevention. (2017). Table 71. Use of Pap smears among women
aged 18 and over, by selected characteristics: United States, selected years 1987–2015.
5.
Centers for Disease Control and Prevention. (2018a). Cancers associated with human
papillomavirus, United States—2011–2015 USCS data brief, no. 4. Atlanta, GA: Centers
for Disease Control and Prevention. 2018a. U.S. Department of Health & Human
Services.
Centers for Disease Control and Prevention. (2018). Catch-up immunization schedule for
persons aged 4 months through 18 years who start late or who are more than 1 month
behind. U.S. Department of Health & Human Services.
Centers for Disease Control and Prevention. (2018b). Human Papillomavirus (HPV) Questions
and Answers U.S. Department of Health & Human Services.
Daley, M. F., Crane, L. A., Markowitz, L. E., Black, S. R., Beaty, B. L., Barrow, J., Babbel, C.,
Gottlieb, S. L., Liddon, N., Stokley, S., Dickinson, L. M., & Kempe, A. (2010). Human
8

Papillomavirus vaccination practices: A survey of US physicians 18 months after
licensure. PEDIATRICS, 126(3), 425–433. https://doi.org/10.1542/peds.2009-3500
Ford, C. A., Skiles, M. P., English, A., Cai, J., Agans, R. P., Stokley, S., Markowitz, L., &
Koumans, E. H. (2014). Minor consent and delivery of adolescent vaccines. Journal of
Adolescent Health, 54(2), 183–189. https://doi.org/10.1016/j.jadohealth.2013.07.028
Healthy People. (2014). Healthy 2020 Objectives. https://www.healthypeople.gov/2020/topicsobjectives/topic/immunization-and-infectious-diseases/objectives
Hughes, C. C., Jones, A. L., Feemster, K. A., & Fiks, A. G. (2011). HPV vaccine decision
making in pediatric primary care: A semi-structured interview study. BMC Pediatrics,
11(1). https://doi.org/10.1186/1471-2431-11-74
Hughes, K., Bellis, M. A., Jones, L., Wood, S., Bates, G., Eckley, L., McCoy, E., Mikton, C.,
Shakespeare, T., & Officer, A. (2012). Prevalence and risk of violence against adults with
disabilities: A systematic review and meta-analysis of observational studies. The Lancet,
379(9826), 1621–1629. https://doi.org/10.1016/S0140-6736(11)61851-5
Javaid, M., Ashrawi, D., Landgren, R., Stevens, L., Bello, R., Foxhall, L., Mims, M., &
Ramondetta, L. (2017). Human Papillomavirus Vaccine uptake in Texas pediatric care
settings: A statewide survey of healthcare professionals. Journal of Community Health,
42(1), 58–65. https://doi.org/10.1007/s10900-016-0228-0
Kepka, D., Berkowitz, Z., Yabroff, K. R., Roland, K., & Saraiya, M. (2012). Human
papillomavirus vaccine practices in the USA: Do primary care providers use sexual
history and cervical cancer screening results to make HPV vaccine recommendations?
Sexually Transmitted Infections, 88(6), 433–435. https://doi.org/10.1136/sextrans-2011050437
Martin, L. R., Williams, S. L., Haskard, K. B., & Dimatteo, M. R. (2005). The challenge of
patient adherence. Therapeutics and Clinical Risk Management, 1(3), 189–199.
Meites, E., Kempe, A., & Markowitz, L. E. (2016). Use of a 2-Dose Schedule for Human
Papillomavirus Vaccination—Updated Recommendations of the Advisory Committee on
Immunization Practices. MMWR. Morbidity and Mortality Weekly Report, 65(49), 1405–
1408. https://doi.org/10.15585/mmwr.mm6549a5
Meites, E., Szilagyi, P. G., Chesson, H. W., Unger, E. R., Romero, J. R., & Markowitz, L. E.
(2019). Human Papillomavirus vaccination for adults: Updated recommendations of the
advisory committee on immunization practices. MMWR. Morbidity and Mortality Weekly
Report, 68(32), 698–702. https://doi.org/10.15585/mmwr.mm6832a3
Milligan, M. S., & Neufeldt, A. H. (2001). The myth of asexuality: A survey of social and
empirical evidence. Sexuality and Disability, 19(2), 91–109.
https://doi.org/10.1023/A:1010621705591

9

Murphy, N. A., Elias, E. R., & for the Council on Children With Disabilities. (2006). Sexuality
of children and adolescents with developmental disabilities. PEDIATRICS, 118(1), 398–
403. https://doi.org/10.1542/peds.2006-1115
National Center for Complementary and Integrative Health. (2017). The use of complementary
and alternative medicine in the United States.
https://nccih.nih.gov/research/statistics/2007/camsurvey_fs1.htm
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. (2019). Genital HPV
Infection—CDC Fact Sheet. https://www.cdc.gov/std/hpv/stdfact-hpv
National Conference of State Legislatures. (2018). HPV vaccine: State legislation and statutes.
http://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-statutes.aspx
National Council on Disability. (2019). Turning rights into reality: How guardianship and
alternatives impact the autonomy of people with intellectual and developmental
disabilities. https://ncd.gov/sites/default/files/NCD_Turning-Rights-intoReality_508_0.pdf
National Institutes of Health. (2010). Fact sheet—Cervical cancer.
Newell, S., & Jordan, Z. (2015). The patient experience of patient-centered communication with
nurses in the hospital setting: A qualitative systematic review protocol: JBI Database of
Systematic Reviews and Implementation Reports, 13(1), 76–87.
https://doi.org/10.11124/jbisrir-2015-1072
Ohana, S., & Mash, R. (2015). Physician and patient perceptions of cultural competency and
medical compliance. Health Education Research, 30(6), 923–934.
https://doi.org/10.1093/her/cyv060
Perkins, R. B., Clark, J. A., Apte, G., Vercruysse, J. L., Sumner, J. J., Wall-Haas, C. L.,
Rosenquist, A. W., & Pierre-Joseph, N. (2014). Missed opportunities for HPV
vaccination in adolescent girls: A qualitative study. PEDIATRICS, 134(3), e666–e674.
https://doi.org/10.1542/peds.2014-0442
Planned Parenthood. (2011). What’s the average age that girls have sex for the first time? Ask
the Experts. https://www.plannedparenthood.org/learn/teens/ask-experts/what-e2-80-99sthe-average-age-that-girls-have-sex-for-the-first-time
President’s Cancer Panel. (2013). Accelerating the HPV vaccine uptake: Urgency for action to
prevent cancer (Annual Report 2012-2013; p. 4).
https://deainfo.nci.nih.gov/advisory/pcp/annualReports/HPV/ExecutiveSummary.htm
Rand, C. M., & Goldstein, N. P. N. (2018). Patterns of primary care physician visits for US
adolescents in 2014: Implications for vaccination. Academic Pediatrics, 18(2), S72–S78.
https://doi.org/10.1016/j.acap.2018.01.002

10

Rosenthal, S. L., Weiss, T. W., Zimet, G. D., Ma, L., Good, M. B., & Vichnin, M. D. (2011).
Predictors of HPV vaccine uptake among women aged 19–26: Importance of a
physician’s recommendation. Vaccine, 29(5), 890–895.
https://doi.org/10.1016/j.vaccine.2009.12.063
Salmon, D. A., Moulton, L. H., Omer, S. B., DeHart, M. P., Stokley, S., & Halsey, N. A. (2005).
Factors associated with refusal of childhood vaccines among parents of school-aged
children: A case-control study. Archives of Pediatrics & Adolescent Medicine, 159(5),
470–476. https://doi.org/10.1001/archpedi.159.5.470
Servais, L. (2006). Sexual health care in persons with intellectual disabilities. Mental
Retardation and Developmental Disabilities Research Reviews, 12(1), 48–56.
https://doi.org/10.1002/mrdd.20093
Stein, S., & Kohut, T. (2015). Attitudes of parents related to the sexuality of adolescent with
developmental disabilities compare to typically developing peers and siblings.
International Society for the Study of Women’s Sexual Health, Austin, TX.
Stokley, S. (2011). Compliance with recommendations and opportunities for vaccination at ages
11 to 12 years: Evaluation of the 2009 National Immunization Survey–Teen. Archives of
Pediatrics & Adolescent Medicine, 165(9), 813.
https://doi.org/10.1001/archpediatrics.2011.138
Taylor, C. J., La Greca, A., Valenzuela, J. M., Hsin, O., & Delamater, A. M. (2016). Satisfaction
with the health care provider and regimen adherence in minority youth with type 1
diabetes. Journal of Clinical Psychology in Medical Settings, 23(3), 257–268.
https://doi.org/10.1007/s10880-016-9460-0
Tissot, A. M., Zimet, G. D., Rosenthal, S. L., Bernstein, D. I., Wetzel, C., & Kahn, J. A. (2007).
Effective strategies for HPV vaccine delivery: The views of pediatricians. Journal of
Adolescent Health, 41(2), 119–125. https://doi.org/10.1016/j.jadohealth.2007.05.007
Walker, T. Y., Elam-Evans, L. D., Singleton, J. A., Yankey, D., Markowitz, L. E., Fredua, B.,
Williams, C. L., Meyer, S. A., & Stokley, S. (2017). National, regional, state, and
selected local area vaccination coverage among adolescents aged 13–17 years—United
States, 2016. MMWR. Morbidity and Mortality Weekly Report, 66(33), 874–882.
https://doi.org/10.15585/mmwr.mm6633a2

11

Review of Literature
Human papillomavirus (HPV) is spread through sexual contact and is ubiquitous amongst
sexually active adults (National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention,
2019). In the United States, it is estimated that 14 million people become newly infected with
HPV each year (Center for Disease Control and Prevention, 2017). Though over 40 distinct
serotypes of HPV are spread via sexual contact, about 14 are identified as high-risk for causing
cancer and genital warts (American College of Obstetrics and Gynecology, 2017; National
Institutes of Health, 2010). The most recent estimates indicate that the HPV infection is
responsible for nearly all cases of cervical cancer, 90% of anal cancers, 65% of vaginal cancers,
70% of oropharyngeal cancers, and 50% of all vulvar cancers (Centers for Disease Control and
Prevention, 2018a). The most recent estimates indicate that over 30,000 new cases of cancer
each year are HPV-attributable (Centers for Disease Control and Prevention, 2018a).
A vaccine to prevent four of the high-risk serotypes of HPV was first approved in 2006
(Centers for Disease Control and Prevention, 2018b). Since the original vaccine was approved
subsequent vaccines to prevent six, and then nine distinct serotypes of HPV were approved and
made available to the public (Joura et al., 2015). The current recommended schedule for the HPV
vaccine includes administration to all children 11-12 years of age but allows for administration to
children as young as nine years of age (Centers for Disease Control and Prevention, 2018b;
Meites et al., 2016). There is also a catch-up vaccine schedule for those who do not receive it as
a child that suggests they do so before they turn 27 (Centers for Disease Control and Prevention,
2018b; Centers for Disease Control and Prevention., 2018c). As of August 2019, the CDC
released an updated HPV vaccine recommendation. The new recommendation indicates the HPV
vaccine can be administered to adults aged 27-45 years, but the benefit of doing so is minimal
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(Meites et al., 2019). If the HPV vaccine series is initiated before 14 years of age, then two doses
of the vaccine are recommended, and if the vaccine is initiated after the age of 14, three doses are
recommended (Centers for Disease Control and Prevention, 2018b).
Despite a national health priority dedicated to increasing the prevalence of adolescents
who receive the HPV vaccine to 80% by 2020, estimates indicate that roughly half of the female
adolescents are currently vaccinated (Healthy People, 2014; Walker et al., 2017). There are
multiple reasons for the suboptimal uptake of the HPV vaccine in the United States. The
President’s Cancer Panels (2013) identified three reasons for suboptimal uptake: missed clinical
opportunities, parental/patient acceptance of the HPV vaccine, and access to the vaccine.
Furthermore, the HPV vaccine is rarely required by schools or daycares and states have
only recently begun debating the possibility of mandated HPV vaccines for children in schools
and daycares (National Conference of State Legislatures, 2018). As such, the disjointed progress
of said legislative efforts makes it difficult to determine with any kind of accuracy how many
schools actually mandate that the students have the HPV vaccine (National Conference of State
Legislatures, 2018). Physicians are split about their beliefs toward mandating students have the
HPV vaccine. Approximately one-third of pediatricians thought the HPV vaccine should be
required, one-third did not think it should be required, and one-third were indifferent (Tissot et
al., 2007). Those who opposed HPV vaccine requirements cited the lack of long-term data
regarding vaccine efficacy and safety and the fact that HPV is sexually transmitted as reasons the
vaccine should not be required by all students (Tissot et al., 2007). Moreover, existing mandated
vaccines generally target infections that are transmitted casually in schools and thus they were
not in favor of making the HPV vaccine mandatory (Tissot et al., 2007).
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Canada, the United Kingdom (UK), and Australia have the most successful HPV
programs in the world (President’s Cancer Panel, 2013). In the UK, the vaccine is offered at
school, which is where 94.4% of those who are vaccinated received the HPV vaccine (Sheridan
& White, 2011). Canada recently initiated a program that provides the HPV vaccine, for free, to
females in the 8th grade. In the first three years of the program, the coverage increased by 8%
(Wilson et al., 2013). Australia also provides the HPV vaccine, free of charge, to 11 and 12 years
old in schools (Cancer Council Victoria, 2019). Australia has a rewards program for parents
whose children are fully vaccinated by five years of age, which has led to high levels of vaccine
coverage (DiGrande, 2019). The widespread coverage of the HPV vaccine in Australia has led
researchers to predict that by the year 2040, the incidence of cervical cancer in women will
decline by 30-68% in women 50+ years of age and by 36%-39% in women who are less than 50
years of age (Castanon et al., 2018). Unfortunately, none of these efforts are present in the
United States; thus, without macro-level changes in our approach to the HPV vaccine, factors
that are congruent with current administrative policies must be examined to be applied in future
interventions.
A Basic Outline of How a Patient Receives Information About the HPV Vaccine
Endorsement by professional organizations is a major predictor for physicians in
accepting and recommending the HPV vaccine (Hswen et al., 2017). One study concluded that a
recommendation to administer the HPV vaccine from the American College of Obstetricians and
Gynecologists (ACOG) would be the most important factor inﬂuencing gynecologists to
recommend the vaccination to their patients (Raley et al., 2004). The American Academy of
Family Physicians (AAFP), American Academy of Pediatrics (AAP), Society of General Internal
Medicine (SGIM), and the Centers for Disease Control and Prevention (CDC) are other
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organizations whose endorsement of the HPV vaccine would persuade more physicians to
recommend it to their patients (Luque et al., 2014; Tissot et al., 2007). To disseminate the
information from the previously mentioned organizations to physicians, pediatricians
recommend grand rounds, written materials, lectures and seminars from local experts, and
accessible online material from those organizations (Tissot et al., 2007).
As all these organizations endorse the HPV vaccine, the next step to examining HPV
vaccine uptake is to examine physicians’ endorsement of the HPV vaccine. Provider
recommendations mediate the relationship between knowledge about the HPV vaccine and
parents getting their children the HPV vaccine (Rahman et al., 2015). A recommendation by a
physician was the greatest predictor of HPV vaccine uptake (Rosenthal et al., 2011). Thus, the
flow of information to promote the HPV vaccine goes as follows: research to demonstrate its
efficacy and safety which is when professional organizations will endorse it. Then physicians
will be more inclined to recommend their patients receive the vaccine. Finally, patients accept
the vaccine for either themselves or their child(ren) (see figure one). The President’s Cancer
Panel (2013), identified three reasons for suboptimal coverage in the United States: missed
clinical opportunities, parental or patient acceptance of the HPV vaccine, and accessibility of the
HPV vaccine. Physicians tend to underpredict vaccine uptake in their practice when a new
vaccine becomes available (Seewald et al., 2013), which should be considered when examining
physician’s anticipation of parents accepting the HPV vaccine.

Research
demonstrating the
vaccine to be safe
and effective

Endorsement from
professional
medical
organizations

Physician’s
recommend
patients receive
the HPV vaccine

Parents or patients
accept the HPV
vaccine

Figure one. The flow of information from basic research to HPV vaccine coverage
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Part One
Target population
The vaccine can be administered through the age of 45 (Centers for Disease Control and
Prevention, 2018b; Meites et al., 2019). Therefore, most people who obtain medical
independence at 18 years of age, if not already vaccinated, can still choose to be vaccinated on
their own accord after the age of 18 without parental consent (National Conference of State
Legislatures, 2018). In a study of just over 100 physicians, 50% of the physicians who worked
with or for a public health care clinic and 30% who worked with or for a private clinic indicated
they would not vaccinate an unaccompanied 17-year-old patient because he or she could not
provide consent (Ford et al., 2014). Nevertheless, it is important to note that parent, partner, and
friend approval were associated with HPV vaccine initiation in people who were 18 years of age
or older (Bendik et al., 2011). Thus, although they do not need parental consent, there are
interpersonal forces that influence the decision to receive the vaccine.
Demographic Factors and HPV Vaccine Initiation.
There were mixed results regarding the uptake of the HPV vaccine by ethnicity. Two
cross-sectional studies reported no association between ethnicity and HPV vaccine uptake (Tiro
et al., 2012; Williams et al., 2013). However, two other research studies reported HPV vaccine
disparities between ethnicities but were inconsistent with regards to which groups were more and
which groups were less likely to have initiated the vaccine. Black and Hispanic women were
more likely than white women to have initiated the vaccine in a survey of pediatricians in a large
southern city (Farias et al., 2017). Bouza & Hammig, (under review) examined a nationally
representative sample of women from the National Survey for Family Growth (NSFG) and
reported black women were less likely to have received the vaccine compared to white women
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but reported no difference between Hispanic and white women. A meta-analysis revealed that no
differences by ethnicity in HPV vaccine initiation when using patient’s self-reported data, but
physicians’ data demonstrated minorities were more likely to initiate the HPV vaccine compared
to white/Caucasian people (Spencer et al., 2019). Moreover, native language, time spent in the
United States, and immigration status were not associated with the HPV vaccine initiation (Tiro
et al., 2012; Williams et al., 2013).
Age and educational attainment in association with the initiation of the HPV vaccine has
also been examined. In a cross-sectional survey, older women (19-22 years and 23-27 years)
were less likely to have initiated the HPV vaccine compared to women who were 18 years of age
(OR=0.24, 95% CI=.11-.52; OR=.09, 95% CI=.04-.18, respectively) (Tiro et al., 2012), which
was similar to results from Farias et al., (2017). Furthermore, there were no differences in HPV
vaccine initiation by a person’s income (Tiro et al., 2012). Women’s educational attainment has
also been examined in the literature. In California, having a bachelor's degree was associated
with higher odds of having received the HPV vaccine compared to having an education that was
less than high school OR=.21, 95% CI=.06-.68, high school graduate OR=.35, 95% CI=.16-.73,
or some college OR=.33, 95% CI=.17-.64 (Tiro et al., 2012). But nationally representative data
did not find an association between educational attainment and the HPV vaccine (Williams et al.,
2013). The major area of study in college may impact the likelihood of receiving the HPV
vaccine. In a cross-sectional sample of 746 male and female students attending a college in the
Midwest, nursing students had the highest prevalence of HPV vaccine initiation followed by
business students, and then medical students (Rohde et al., 2018).
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Sexuality in Association with the Receipt of the HPV Vaccine.
Given the inherent connection between HPV and sexuality, women’s sexual experience
in association with the HPV vaccine has been examined in previous research. In a cross-sectional
study, the number of oral sex partners a college student reported was not related to the initiation
of the HPV vaccine (Rohde et al., 2018). However, in a separate cross-sectional study,
penetrative sex revealed different results (Bendik et al., 2011). In this study ever having sex was
associated with higher odds of HPV vaccine initiation in female undergraduate students aged 1824 years compared to those who had never had sex (N=1,975) (Bendik et al., 2011).
Furthermore, in a cross-sectional sample from California, compared to women with two or more
sex partners, women with zero sex partners were less likely to have ever initiated the HPV
vaccine OR=0.40, 95% CI =0.22-0.72 (Tiro et al., 2012). Similarly, students who had 1-3
penetrative sex partners were more likely to have received and completed the HPV vaccine series
compared to people with zero sex partners (OR=1.78, 95% CI=1.07-2.95) (Rohde et al., 2018).
However, this study did not reveal a dose-response as people with four or more sex partners were
not more likely to have received or completed the HPV vaccine compared to those with zero
penetrative sex partners (Rohde et al., 2018). Nationally representative data from the 2006-2010
NSFG demonstrated women (N=3,253) aged 15-25 years of age who had no sexual partners in
their lifetime were less likely to have initiated the vaccine compared to women who only had
male partners in their lifetime (Agénor et al., 2016; Gelman et al., 2013); the cell size for women
who only had same-sex partners in their lifetime was too small for analyses. In later years of the
NSFG, the number of male sex partners a woman reported demonstrated a dose-response type
pattern with the odds of initiating the HPV vaccine (Bouza & Hammig, under review).
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A review study concluded, the perceived severity of the consequences of HPV is high in
women but not related to HPV vaccine uptake (Brewer & Fazekas, 2007). Therefore, it might be
that sexually active women may have higher perceived susceptibility of contracting HPV
compared to women who are not sexually active. The following evidence demonstrates how
relationship status influences a woman’s perceived likelihood of contracting HPV. In a
qualitative study, college women (18-26 years of age) in Florida were interviewed (N = 50)
(Thompson et al., 2017). In this study, women in a committed relationships did not see
themselves as at-risk for contracting HPV because they were monogamous and had few sexual
partners (Thompson et al., 2017). Women who were dating perceived their HPV risk as higher
because of their engagement in unprotected sexual activity (Thompson et al., 2017). Single
women believed their risk of contracting HPV was low because of sexual inactivity (Thompson
et al., 2017). The differences in perceived susceptibility may translate to differences in HPV
vaccine coverage between women in committed relationships and women not in committed
relationships. For example, marital status (married, living with a partner, or other) was not
associated with HPV vaccine initiation in women aged 18-27 years (Tiro et al., 2012). However,
women who were not married were more likely to have received the HPV vaccine compared to
women who were married in a sample of women aged 18-26 years from the NHIS (2010)
(Williams et al., 2013). Finally, one study examined differences between women with different
sexual orientations. There were no differences between individuals based on their sexual
orientation (heterosexual, bisexual, and lesbian) for awareness of the HPV vaccine; however, cell
size was too small to compare for differences in the initiation of the vaccine between individuals
of various sexual orientations (Agénor et al., 2015).
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Health Statuses, Health Behaviors, and Health Insurance.
In a national sample of physicians who primarily worked in teaching hospitals, 14-33%
of respondents reported using a patient’s positive HPV test results as an indicator to recommend
the HPV vaccine (Kepka et al., 2012). In that same study, 10-33% of physicians recommended
the HPV vaccine to women upon receiving test results of a patient’s abnormal pap smear (Kepka
et al., 2012). Furthermore, women who have genital warts had greater odds of receiving the HPV
vaccine compared to individuals who did not have genital warts (p=.021) (Bendik et al., 2011).
However, it is unclear if these test results lead to women initiating the HPV vaccine. Once
women have already contracted a specific serotype of the HPV, the HPV vaccine is less effective
(Meites et al., 2019), therefore it is disadvantageous to use women’s HPV-positive status as an
indicator that the HPV vaccine is needed.
Women who have had a pap smear were no more likely to have initiated the HPV vaccine
compared to women who had never had a pap smear (Tiro et al., 2012). However, this study was
not nationally representative and did not take into consideration the results of the pap smear test,
which we know impact some physicians’ recommendations (Williams et al., 2013), and did not
consider the age in which the participant received the HPV vaccine. The age is important
because the age in which the HPV vaccine is recommended is likely not at an age when a female
is receiving pap smears. Therefore, without examining age as a covariate, the variable of
receiving a pap smear alone has its faults as a predictor for receiving the HPV vaccine.
Previous research demonstrated that women who received infant vaccines and the flu
vaccine were more likely to have received the HPV vaccine compared to women who did not
receive their infant vaccines or a recent flu vaccine (Williams et al., 2013). However, not all
research corroborates the association between receiving the flu vaccine and receiving the HPV
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vaccine (Tiro et al., 2012). Receiving a physician’s recommendation to obtain the HPV vaccine
is strongly associated with receiving the HPV vaccine (Rosenthal et al., 2011). As receiving a
recommendation from a physician is contingently reliant upon seeking health care, previous
research has examined the association between receiving health care and receiving the HPV
vaccine. In women 18-27 years of age, not having a usual source of health care other than the
emergency room, was not associated with the initiation of the HPV vaccine; however, this study
only examined women in California and therefore may not be generalizable across the entire
country (Tiro et al., 2012). In a nationally representative survey from the NSFG, having a usual
source of health care was positively associated with receiving the HPV vaccine (OR = 2.45, 95%
CI = 1.49-4.02) (Gelman et al., 2013). Moreover, women who had not visited any health care
provider in the last year were less likely to have initiated the HPV vaccine (OR=.23, 95 %
CI=.08-.73) (Tiro et al., 2012). Similar results were demonstrated in a nationally representative
sample of women from the NHIS (2010) (Williams et al., 2013). Women who saw a physician in
the past year were more likely to have received the HPV vaccine compared to women who had
not seen a physician in the previous year (Williams et al., 2013). Therefore, we can conclude
seeking annual care from a physician appears to be positively associated with HPV vaccine
initiation.
The association between having a usual source of health care or seeing a physician in the
last year and receiving the HPV vaccine is great for the people who seek routine health care but
problematic because it is estimated one-third of individuals aged 11-21 years (a large portion of
the population who are eligible to receive the HPV vaccine) do not receive annual preventative
health care (Rand & Goldstein, 2018). After the age of 16, only 14% of females received yearly
preventative visits (Rand & Goldstein, 2018). In females, those aged 10-19 years have the lowest
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rate of seeking ambulatory health care (about 1.5-2.5 annual visits per capita), which by
definition would include preventative care, followed by females aged 20-29 years (about 1.752.5 annual visits per capita) (Fortuna et al., 2009). This may be in part because there are no
universally accepted recommendations for preventative medicine for young adults aged 18-26
years (Ozer, 2012). Furthermore, individuals who possess health insurance were more likely to
seek routine preventative health care compared to their uninsured counterparts (Simon et al.,
2017). In a sample of young adults aged 20-29 years, 58.2% of those with private insurance
sought ambulatory care, 11.8% with public health insurance, and 10.4% with no health insurance
(Fortuna et al., 2009).
It is at these preventive health care visits in which over half of vaccines are received
(Rand & Goldstein, 2018). Vaccines may not always be administered when a person is sick or
unwell (Center for Disease Control and Prevention, 2014). In an online nationally representative
sample of physicians, 41% reported discussing vaccines at sick visits, and 73% of the physicians
who did, mentioned the HPV vaccine (Gilkey, Moss, et al., 2015). Thus, a recommendation to
receive the HPV vaccine at sick visits still occurs irrespective of whether the physician will
administer it at that time.
A qualitative study in a nationally representative sample of adults reported nearly 25% of
people who avoided seeking health care did so because the costs were prohibitive (Taber et al.,
2015). The majority (78.4%-84%) of the people in that sample possessed health insurance,
suggesting irrespective of health insurance status, cost (or perceived cost) was inhibitory to
seeking health care (Taber et al., 2015). This may be in part because few people understand the
benefits and coverage included in their health insurance plans (e.g., people may not know all
insurance plans are required to cover the cost of the vaccine) (Loewenstein et al., 2013). Only
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10-15% of people are able to calculate an accurate estimation of costs when seeking health care
and typically overestimate the restrictions of their health care plans (Loewenstein et al., 2013).
Hence, it is possible the cost of medical care is a perceived, but not actual, barrier to accessing
the HPV vaccine. At Planned Parenthood, without health insurance, the HPV vaccine can cost up
to $250 per dose (Planned Parenthood, 2019). Therefore, the cost of the vaccine without health
insurance is likely unaffordable to a large group of people.
Although HPV vaccine acceptability does not differ between people with and without
health insurance (for a review see, Brewer & Fazekas, 2007), actual uptake of this preventative
behavior between those with private health insurance, public health insurance, and no health
insurance is complicated (Farias et al., 2017; Gelman et al., 2013; Tiro et al., 2012; Williams et
al., 2013; Bouza & Hammig, under review). The HPV vaccine is included in the Federal
Vaccines for Children (VFC) program, which provides free vaccines to adolescents 19 years of
age or younger (Center for Disease Control and Prevention, 2016b). Additionally, under the
Affordable Care Act (ACA), all insurance plans must cover the cost of the HPV vaccine (Center
for Disease Control and Prevention, 2016b). Therefore, most people should have equal coverage
for the vaccine regardless of health insurance status. This might explain the inconsistent results
regarding the association between health insurance status and the HPV vaccine (Farias et al.,
2017; Gelman et al., 2013; Tiro et al., 2012; Williams et al., 2013, Bouza and Hammig, under
review). Data from the 2010 NHIS demonstrated insurance status was not associated with
receiving the HPV vaccine (Williams et al., 2013). In a survey specific to persons living in
California, compared to people with private health insurance, people with public health insurance
were less likely to have initiated the HPV vaccine, OR=.29, 95% CI=.14-.63, but there was no
difference between people with private health insurance and those without health insurance (Tiro

23

et al., 2012). However, there was a difference between people with private health insurance and
no health insurance with regards to the reception of the HPV vaccine in two studies; but, there
was no difference between public and private insurance in the same two studies (Gelman et al.,
2013; Bouza & Hammig, under review). Yet entirely different results were revealed in another
study (Farias et al., 2017). Women with public health insurance were more likely to have
initiated the HPV vaccine compared to women with private health insurance (OR=1.36, 95%
CI=1.28-1.43) (Farias et al., 2017). Thus, the literature regarding insurance status and the HPV
vaccine is inconclusive.
Complementary and Alternative Medicine (CAM).
The type of health care provider may impact the likelihood of receiving an HPV vaccine
recommendation. Thus far in the literature, researchers have examined nearly exclusively
primary care specialties pediatricians, family practitioners, and OBGYNs. Previous researchers
were interested in determining if HPV vaccine recommendations varied by primary care
specialty. Newly licensed physicians were surveyed about their HPV vaccine recommendations
practices through a national network of primary care physicians (Daley et al., 2010). How
strongly the physicians recommended the HPV vaccine did not differ between family
practitioners and pediatricians (Daley et al., 2010). This study had a high response rate of 79%81%, thus contributing to the strength of this study (Daley et al., 2010). There is more
information, however, regarding differences in the consistency of providing an HPV vaccine
recommendation between various primary care specialties. In four out of five studies,
pediatricians were more likely to report always recommending the HPV vaccine to all age groups
of patients (11-12, 13-17, 18-26 years) compared to family practitioners and OBGYNs (Barnack
et al., 2010; Gilkey et al., 2015; Malo et al., 2014; Vadaparampil et al., 2011). There was only
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one study, specific to Hawaiian physicians, that reported no differences by physician specialty
regarding the consistency of their recommendations to receive the HPV vaccine (Soon et al.,
2015). Consequently, it appears pediatricians may be the most consistent recommenders of the
HPV vaccine out of the specialties that are routinely included in the literature.
Recently in the United States, there has been an increase in complementary and
alternative medicine (CAM) use (National Center for Complementary and Integrative Health,
2017). Often, this refers to naturopathic or homeopathic medicine. According to the American
Association of Naturopathic Physicians, a naturopathic doctor diagnoses, prevents, and treats
acute and chronic illness to restore and establish optimal health by supporting the person's
inherent self-healing process (The American Association of Naturopathic Physicians, 2018).
Less than half of the states in the US recognize naturopathic providers’ system of licensure,
regulation, and scope of practice and as such insurance coverage varies from state to state
(Healy, 2012; The American Association of Naturopathic Physicians, 2018). Unlike naturopathic
doctors, homeopathic doctors do not have a recognized scope of practice anywhere in the US
(American Institute of Homeopathy, 2007). Homeopathic practitioners do not have licensure but
rather provide training for certification in homeopathic practice (American Institute of
Homeopathy, 2007). However, the American Institute of Homeopathy bypasses laws for
practicing “medicine” by only providing certification to people who already have a Medical
Doctor (M.D.) or Doctor of Osteopathy (D.O.) degree (American Institute of Homeopathy,
2007). Homeopathic medicine is treating health ailments with the lowest possible dose of the
substance in which made the person ill in the first place and can only prescribe one remedy at a
time (American Institute of Homeopathy, 2007). Naturopathic doctors incorporate homeopathic
medicine in their practice (The American Association of Naturopathic Physicians, 2018).
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There is a high prevalence (67%) of concern about vaccine safety for at least one vaccine
among naturopathic doctors (Whitman, 2016). One group of researchers examined 330
naturopathic websites (Caulfield et al., 2017). Of the over 300 websites, 40 promoted vaccine
hesitancy, 26 offered an alternative to vaccines, and 53 contained vaccine-hesitant rhetoric
(Caulfield et al., 2017), suggesting naturopathic practitioners are hesitant about vaccines. A
survey of 145 naturopathic doctors (low response rate 28.7%) reported that almost all (93%)
naturopathic doctors discuss vaccines with their patients (Whitman, 2016) – a finding that may
actually be counterproductive for the public’s health. Creating a customized vaccine schedule
that includes only select vaccines, spreading vaccines out over a greater time period, or delaying
vaccinations was reported by 70% of the naturopathic doctors who were surveyed (Whitman,
2016). The CDC does not endorse any alternative vaccine schedule as it has no benefits to the
child (Center for Disease Control and Prevention, 2019). Consequently, naturopathic doctors
may be a source of false information that contributes to the vaccine-hesitant culture. In fact,
often people who accept naturopathic care fear vaccines and reject their use (Tissot et al., 2007).
Children who have seen CAM practitioners are up to four times less likely to receive the
influenza vaccine compared to children who have never seen a CAM practitioner (Bleser et al.,
2016; Salmon et al., 2005). However, no research has yet examined CAM use in association with
the uptake of the HPV vaccine.
Patient Adherence to Medical Providers’ Recommendations.
Despite the strong association between a provider’s recommendation to receive the HPV
vaccine and actual uptake of the HPV vaccine uptake (Rosenthal et al., 2011), it is possible that
the interpersonal relationship and communication between patients and physicians may influence
a patient’s adherence to the recommendation. Patient-centered care involves the physician

26

extending an invitation to the patient to be an active participant in their health care (Teas Gill,
2005) and includes being respectful of the patient’s preferences, needs, and values, and including
them in the provider’s recommendations (Newell & Jordan, 2015). Pediatricians previously
recognized the importance of considering the patient’s values when recommending the HPV
vaccine (Tissot et al., 2007). Pediatricians reported it is important to customize their approach to
the HPV vaccine when the patient identifies with a conservative religion because recommending
the vaccine may appear as if you are condoning the behavior [sex] associated with it (Tissot et
al., 2007). Furthermore, pediatricians believe a culturally-appropriate approach to recommending
the HPV vaccine to black people is needed as pediatricians perceive them to be less trusting of
the medical community compared to other ethnic groups (Tissot et al., 2007).
As part of patient-centered care entails the inclusion and respect of the patient’s values
(Newell & Jordan, 2015), physicians who understand their patient's values or share the same
values as their patients have a unique opportunity in their patient’s life to make impactful and
meaningful medical recommendations. Patients reported a greater likelihood to comply with their
physician’s recommendations when the patient perceived the physician as culturally competent
regarding their culture (Ohana & Mash, 2015). Furthermore, when a patient viewed their
physician as similar to them in personal beliefs, values, and communication, the patient was
more likely to adhere to their physician’s recommendations (Street et al., 2008). Clinicians are
recommended to try to empathize with the patient as a means to increase the prospect the patient
will accept the vaccine (Henninger et al., 2017).
Sharing a similar culture facilitates the development of interpersonal trust (Good, 2000;
for a review see, Stolle, Soroka, & Johnston, 2008). Two people of different cultural
backgrounds can establish trust through repeated exposure, but without exposure, there will
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likely be lower levels of trust between a diverse dyad than a similar dyad (Stolle et al., 2008).
Parents who felt distrust for their children’s physicians were less willing to vaccinate their
daughters against HPV than those who trusted their physicians (Otanez & Torr, 2018). Fathers
who trusted their medical providers had greater intentions to vaccinate their children against
HPV than fathers who did not trust their medical providers (MacArthur, 2017). Gaining the trust
of a patient prior to recommending the HPV vaccine is recommended as a strategy to increase
HPV vaccine uptake (Henninger et al., 2017).
A patient-centered approach to medical care can increase the patients’ adherence to their
physician’s recommendations and directions (Robinson et al., 2008). A systematic literature
review determined that when physicians incorporated their patient’s opinions and input into their
expert judgment, patients had high satisfaction with their health care (Naidu, 2009). Routinely,
research demonstrates patients who are satisfied with their health care are more likely to adhere
to recommendations than patients who are not satisfied with their health care (Bogart et al.,
2004; Gross et al., 2003; Taylor et al., 2016). However, previous research also suggests that after
controlling for race/ethnicity, income, and educational attainment, the association between
patient satisfaction and adherence to physician recommendations was weakened (Jerant et al.,
2014). This research highlights the importance of culturally competent physicians or a shared
culture between patient and physician as a potential means to increase the uptake of the HPV
vaccine. However, outside a patient’s level of trust in their physician and recommendation for
physicians to be culturally sensitive, the relationship between a patient seeing a physician who is
culturally similar to them and the HPV vaccine uptake has not yet been examined.
Moreover, the medical field is notorious for using language that is incomprehensible to a
layperson, which results in patients not understanding physician recommendations and directions
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(Martin et al., 2005). The World Health Organization (WHO) recommends having
comprehensible information available for consumers of the HPV vaccine (World Health
Organization, 2017). The use of comprehensible information increased positive attitudes about
the HPV vaccine and decreased concerns about the HPV vaccine in an online pilot study
designed to provide easily understandable information about HPV and the HPV vaccine (Starling
et al., 2014). As such, physicians try to dispel fears and misunderstandings about the HPV
vaccine by avoiding the use of medical jargon (Widman et al., 2018). Therefore, patients who
see physicians who use comprehensible language may be more likely to accept the HPV vaccine
compared to patients who do not receive comprehensible information from their physicians.
Thus, the purpose of this study was to investigate women’s health care behaviors and
characteristics of the health care they received. The sample was limited to women who were
between 18 and 26 years of age and the data came from the National Health Interview Survey
(NHIS) for the year 2017. The NHIS does not survey females under the age of 18 years and the
age cut-off to receive the vaccine in 2017 was 26 years of age, thus we limited the age of our
sample accordingly. Finally, as males are not socialized to receive urogenital care as females are,
the sex of the sample was also limited (Smith et al., 2006).
Part Two
Parent’s Role in the Initiation of the HPV Vaccine
Although some parents want their children involved in the decision to get the HPV
vaccine (Olshen et al., 2005), teens do not see themselves as having agency in the decision to
receive the HPV vaccine (Hughes et al., 2011). The teens may express their dislike of needles
but then acknowledge that is their parent’s decision, not theirs, to receive the HPV vaccine
(Hughes et al., 2011). Consequently, parents play a significant role in their children’s uptake of
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the HPV vaccine and parents not accepting the HPV vaccine is one of the three identified reasons
for low HPV vaccine coverage in the United States (President’s Cancer Panel, 2013).
Parent’s Demographic Factors.
There were mixed results regarding religion and the HPV vaccine. Four months after the
approval of the HPV vaccine, 100 parents were called and interviewed about their intentions to
have their children vaccinated for HPV (Barnack et al., 2010). In this study, religious service
attendance was positively correlated to the parent’s intentions to have their child(ren) vaccinated
and explained 27.8% of the variance (Barnack et al., 2010). Similarly, parents who frequently
attended religious services had greater odds of deciding to not vaccinate their daughters
(OR=2.92, 95% CI =1.25–6.84) compared to those who did not attend religious services (Shelton
et al., 2013). However, parents with moderate religious service attendance had slightly greater
odds of already having their daughters vaccinated than parents who did not attend religious
services (OR=3.07, 95% CI=1.16-8.11) (Shelton et al., 2013). Contrarily, another cross-sectional
study of parents reported those who never or rarely go to church have higher intentions (6.22 out
of 7) of getting their children vaccinated compared to parents who attend church 1-3 times per
month (5.06 out of 7), and parents who attend church more than one time per week (4.45 out of
7) (Barnack et al., 2010). Thus, the literature revealed mixed results between religious service
attendance and HPV vaccine uptake.
Furthermore, religious affiliation instead of religious service attendance has been
examined. In a sample of 476 white, black, and Hispanic parents, there were no differences
between various Christian religious denomination and deciding not to have their female children
(9-17 years of age) receive the HPV vaccine (Shelton et al., 2013). However, identifying as
Catholic was associated with greater odds of already vaccinating one’s daughter compared to
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parents who did not affiliate with a specific religious denomination (OR=3.26, 95% CI = 1.0610.06); but, there was no difference between nonaffiliated persons and protestants or other
Christian religions (Shelton et al., 2013). Thus, children of Catholic parents have may greater
coverage of the HPV vaccine compared to children of parents who affiliate with other religions
or no religion.
Most of the research examining race/ethnicity and parental acceptance of the HPV
vaccine demonstrated no relationship. There were no differences between race/ethnicity
regarding the parental rejection of the HPV vaccine in a cross-sectional study of parents who
recently took their child to a family practitioner or pediatrician (Rand et al., 2011). Similarly,
two cross-sectional studies demonstrated parental acceptance of the HPV vaccine for their
daughters did not differ by race/ethnicity (Gerend et al., 2009; Tiro et al., 2012). However, one
nationally representative cross-sectional survey reported black parents had a greater likelihood of
getting their daughter vaccinated compared to white parents (OR=1.37, SE=.16), but there were
no differences between Hispanic or Asian parents and white parents (Otanez & Torr, 2018).
Furthermore, in a survey of parents in California, the time spent in the United States did not
impact the uptake of the HPV vaccine for their children (Tiro et al., 2012).
Parents socioeconomic factors in association with their acceptance of the HPV vaccine
demonstrated little consistency in the literature. Parents with some college (OR=.70, 95% CI =
.50-.79) and parents who only completed high school (OR=.63, 95% CI = .46-.87) were less
likely to have their children vaccinated compared to parents with a college degree (Tiro et al.,
2012). This was similar to Gelman et al., (2013) who revealed a dose-response relationship
between educational attainment and HPV vaccine initiation. Thus, Gelman et al., (2013) and Tiro
et al., (2012) demonstrated college-educated parents were more likely to vaccinate their children
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than parents without a college degree. However, a different study presented an inverse
relationship between educational attainment and the likelihood of receiving the HPV vaccine
(Otanez & Torr, 2018). Parents who did not finish high school and parents who had a college
degree were respectively more (OR=1.30, SE=.09) and less likely (OR=.89, SE=.07) to have
their children vaccinated than were parents who only finished high school (Otanez & Torr,
2018). Therefore, in this study, parents who did not complete high school had the greatest
acceptance of the HPV vaccine for their child and college-educated parents had the lowest
acceptance of the HPV vaccine (Otanez & Torr, 2018). Therefore, a conclusion about parental
education and parental acceptance of the HPV vaccine cannot be made. Furthermore, parental
income demonstrated an inconsistent association with HPV vaccine uptake in their children as
well (Gelman et al., 2013; Gerend et al., 2009).
In a nationally representative cross-sectional survey, single parents and divorced parents
were more willing to vaccinate their daughters than were married parents (Otanez & Torr, 2018),
but this was not consistent across all studies (Gerend et al., 2009; Tiro et al., 2012). Parent’s
gender was not associated with HPV vaccine initiation for their child (Tiro et al., 2012); but in a
more recent study, female parents were less likely to vaccinate their children compared to male
parents (Otanez & Torr, 2018). Parent’s age and odds of having their child(ren) vaccinated did
not demonstrate consistent results across the literature either (Gerend et al., 2009; Otanez &
Torr, 2018; Tiro et al., 2012). Otanez & Torr (2018) reported parents who were 35-54 years of
age were more likely to vaccinate their children compared to parents who were 18-34 years of
age, but parents 55 years of age and older did not differ from the youngest parents. Tiro and
colleagues (2012) and Gerend and colleagues (2009) found no relationship between parent’s age
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and their children receiving the HPV vaccine. There appears to be no parental socioeconomic
factors that are consistently linked with greater acceptance of the HPV vaccine for their child.
Parent’s Understanding of HPV and the HPV Vaccine.
Knowledge about the HPV vaccine, but not HPV, was associated with having a
vaccinated child (Gerend et al., 2009); however, both were associated with intent to vaccinate
one’s child (Anderson et al., 2018). Parents in rural Alabama reported that if the medical
community provided information about the HPV vaccine such as its purpose, importance, side
effects, and safety, it would increase the likelihood of parents accepting the vaccine for their
child (Boyd et al., 2018). Yet, 71.6% of women reported that the topic was not at all mentioned
or discussed in their most recent health care visit for their child (Cermak et al., 2010).
The constructs of the Health Belief Model can be used to examine parents’ intentions to
vaccinate their children against HPV. The perceived benefits of receiving the HPV vaccine were
primarily associated with the prevention of cancer or genital warts. Parents who believed their
child’s health would be better because of the HPV vaccine were more likely to vaccinate their
child (Anderson et al., 2018; Gerend et al., 2009). Parents who believed the HPV vaccine
prevented cancer were more likely to get their child vaccinated than were parents who were
unsure or did not know about the association between HPV and cancer, OR=9.55, 95% CI =
4.29–21.36 (Anderson et al., 2018). Parents were more confident in their decision to have their
child(ren) vaccinated when the information provided to them about the vaccine acknowledged
cancer prevention (Shah et al., 2019). Consequently, the perceived benefits of the vaccine were
linked to the parent’s perceived severity of HPV (e.g., understanding HPV can lead to serious
conditions such as cancer). Parents who understood the negative consequences of HPV were
more likely to vaccinate their child(ren) (Barnack et al., 2010). Likewise, parents who knew that
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HPV could cause genital warts and cervical cancer were more likely to get their children
vaccinated compared to parents who were unsure or did not realize that HPV led to genital warts
and cervical cancer (Anderson et al., 2018). Parents who knew HPV could cause cervical cancer
were 2.57 times more likely to have had a conversation about the HPV vaccine with their
physician (Gamber et al., 2019).
The child’s biological sex had little impact on the acceptability of the HPV vaccine in
small studies, but large-scale studies suggest parents are more inclined to vaccinate their female
children than their male children (Brewer & Fazekas, 2007; McRee et al., 2014). Parents may
believe women are more susceptible to the negative consequences of HPV than males because of
the strong connection between HPV and cervical cancer (Centers for Disease Control and
Prevention, 2018a) and because there is no test to determine if men have HPV (Center for
Disease Control and Prevention, 2016a). However, in a sample of 246 parents from North
Carolina, with sons aged 9-21 years, 76% of them reported the ability to reduce transmission of
HPV from their son to their female partners contributed to their decision to vaccinate their male
children (Schuler et al., 2014). Suggesting that the desire to protect women against cervical
cancer impacts the likelihood of both male and female children receiving the vaccine.
Parent’s perceived barriers to having their child receive the HPV vaccine were often
related to their perception of the vaccine’s safety. The parent’s perception of the HPV vaccine’s
safety was inversely associated with refusing the vaccine (Rand et al., 2011). Hughes and
colleagues (2011) corroborated Rand's and colleagues' work but also revealed that parents delay
the reception of the HPV vaccine for their child because they have concerns about its efficacy as
well. While parents who trusted the FDA’s approval as a marker of safety were more likely to
vaccinate their daughters (Gerend et al., 2009). Not receiving an appropriate recommendation
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was another barrier to parental acceptance of the vaccine (Javaid et al., 2017). Perkins and
colleagues (2014) revealed the same results as Javaid and colleagues (2017) but added that some
parents believed their providers discouraged the HPV vaccine initiation which was an additional
barrier to having their child vaccinated.
Another perceived barrier experienced by parents was the fear that the HPV vaccine will
change the trajectory of their child’s sexual debut or lead to engagement in riskier sexual
behaviors (Daley et al., 2010; Soon et al., 2015). Parents know they will likely be unaware of the
timing of their child’s sexual debut (Perkins et al., 2014). However, that does not stop parents
from letting their fear about the HPV vaccine leading their child to an earlier sexual debut, stop
them from refusing the vaccine for their child (Soon et al., 2015). Parental fear of an earlier
sexual debut or engagement in riskier sex behaviors due to receiving the HPV vaccine was
reported by 41% of pediatricians and 46% of family practitioners (Daley et al., 2010). These
findings likely partially explain why some parents did not tell their children they were protected
from an STI (Olshen et al., 2005). Other parents prefer teaching abstinence-only until marriage
type of sexuality education as a way to prevent the transmission of HPV rather than the vaccine
(Olshen et al., 2005). These parents believe teaching their children not to be promiscuous will
prevent their children from contracting HPV and therefore deem the vaccine unnecessary
(Olshen et al., 2005).
A parent’s perceived susceptibility for their child contracting HPV was highly dependent
on their perception of their child as a sexual being or sexually active. Parents who perceived their
child as at risk for contracting HPV were more likely to have that child vaccinated (Barnack et
al., 2010). Sometimes parents perceive the vaccine as unnecessary at the time when physicians
recommend the vaccine (Perkins et al., 2014) and delay its administration because they do not
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believe their child is at risk for HPV (Hughes et al., 2011). This is often found in parents who do
not perceive their child as sexually active at the time a physician recommends the vaccine (often
11-12 years of age) (Javaid et al., 2017; Perkins et al., 2014).
Physician’s Role in HPV Vaccine Coverage
Disparities in Physicians’ Recommendations.
Physician’s HPV vaccine recommendations vary by demographic factors. For example,
in a nationally-representative cross-sectional sample (N=1,538) of pediatricians, gynecologist,
and family practitioners, physicians who were 40-49 years of age were more likely to always
recommend the HPV vaccine to early adolescents than were the physicians who were 50+ years
of age, but there was no difference between the youngest age group (25-39-years) and the 50+
year group (Vadaparampil et al., 2011). In the same study, physicians who identified their
race/ethnicity as anything other than white/Caucasian were more likely to recommend the HPV
vaccine than were white/Caucasian physicians (Vadaparampil et al., 2011). Consistently,
research demonstrated the physician’s gender does not change the likelihood of recommending
the HPV vaccine to female patients (Gilkey, Malo, et al., 2015; Soon et al., 2015; Vadaparampil
et al., 2011). Consequently, it appears middle-aged physicians who are not white/Caucasian are
recommending the HPV vaccine most commonly.
There is an uneven distribution of the HPV vaccine in the country. The northeast region
of the country has the highest coverage, followed by the west coast (Center for Disease Control
and Prevention, 2018). As such, the region of the country in which a physician practiced
medicine as it relates to their HPV recommendations has also been examined. In a crosssectional mail and return survey, pediatricians, family practitioners, and OBGYNs who practiced
medicine in the western region of the United States were slightly less likely to recommend the
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HPV vaccine to patients compared to physicians practicing in the northeast region (Malo et al.,
2014). Thus, providing a possible explanation about the uneven coverage of the HPV vaccine
between those two regions of the country. However, there were no differences between the
physicians in the western region of the US and physicians in the midwest or southern regions
(Malo et al., 2014). Furthermore, there were no differences between regions of the US and the
strength of the physician’s HPV vaccine recommendation (Allison et al., 2016; Gilkey, Malo, et
al., 2015). Response rate in Malo et al., (2014) study was moderately high (59.72%); however,
40% of physicians did not return the survey and the non-response is a potential form of bias.
Physician’s Strategies to Increase HPV Vaccine Coverage.
Physicians who had zero strategies for ensuring completion of HPV series were less
likely to recommend the HPV vaccine than were physicians who had two or more methods of
ensuring series completion (Vadaparampil et al., 2011). The strategy options available for
physicians to choose from were the following: providing reminder cards, reminder letters or
phone calls, flagging patient charts, scheduling patients for the next dose during their current
office visit, using a computerized database or registry, or other. This study was the only study
that examined strategies for increasing the completion of the HPV vaccine series, other research
focused on strategies to increase acceptance of the first HPV vaccine dose.
In two studies, one a nationally representative cross-sectional survey of physicians and
the other a qualitative study of physicians in Philadelphia, respondents reported discussing the
HPV vaccine with parents as a routine part of the adolescent vaccine regimen (Gilkey et al.,
2015; Hughes et al., 2011). Physicians were more likely to mention the HPV vaccine if they
believed parents were more likely to accept the HPV vaccine when discussed in the context of
other vaccines (Allison et al., 2016). In another cross-sectional nationally representative survey
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of physicians, 67% of pediatricians and 70% of family practitioners believed the introduction of
meningococcus and pertussis vaccines for adolescents made it easier to recommend the HPV
vaccine (Daley et al., 2006). This suggests the integration of the HPV vaccine with other,
potentially more well-known vaccines is indeed making it easier for physicians to provide a
recommendation for the HPV vaccine. One experimental study demonstrated that this approach
resulted in a small increase in the initiation of the HPV vaccine (Malo, Hall, Brewer, Lathren, &
Gilkey, 2018). The theory behind addressing the HPV vaccine as routine is that it will increase
parents’ perception of adolescents receiving the HPV vaccine as the social norm, as outlined by
the Theory of Planned Behavior (TPB) (Malo et al., 2018).
The constructs of TPB have been used to predict physician’s intentions to recommend the
HPV vaccine (Askelson et al., 2010; Roberto et al., 2011). Attitudes toward the behavior
[recommending the HPV vaccine] included favorable attitudes about recommending the HPV
vaccine and believing it was good for their patients. Social norms of recommending the HPV
vaccine included physicians believing the people who were important to them [the physician]
wanted them [the physician] to recommend the HPV vaccine, believed it was expected of them
[the physician], and believed people in their profession, whose opinions they valued wanted
them [the physician] to recommend the HPV vaccine. Attitudes toward the behavior and social
norms were stronger predictors of pediatricians recommending the HPV vaccine compared to
perceived behavioral control in both studies (Askelson et al., 2010; Roberto et al., 2011).
Perceived behavior control was measured by physician’s beliefs that it was easy to get the patient
to accept the vaccine and cost preventing physicians from being able to vaccinate their patients.
Based on these findings, attitudes about administering the HPV vaccine and the perception of
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administering the HPV vaccine as the socially accepted “norm” is driving physician’s HPV
vaccine recommendations.
Not all physicians discussed the HPV vaccine as a routine health care behavior. Other
physicians discussed the benefits and drawbacks of the HPV vaccine and allowed the
parent/patient to decide if they want to receive the vaccine. In a cross-sectional, nationally
representative survey of physicians, 25% of them reported presenting the HPV vaccine to
parents/patients as optional and presented the pros and cons of receiving it (Gilkey, Malo, et al.,
2015). The more pros/benefits the physician perceived of receiving the HPV vaccine, the more
likely he or she was to strongly recommend vaccination (Gilkey, Malo, et al., 2015). Some of the
pros or benefits physicians believed regarding the HPV vaccine were that it can prevent cervical
cancer, other cancers, and genital warts (Gilkey, Malo, et al., 2015). Physicians who believed the
HPV vaccine could prevent multiple cancers were more likely to strongly recommend the
vaccine compared to physicians who believed the HPV vaccine only prevented cervical cancer
and genital warts or only cervical cancer (Gilkey, Malo, et al., 2015). Nevertheless, some
physicians felt there were drawbacks to the HPV vaccine. One of the cons or drawbacks to the
HPV vaccine included dissatisfaction with the amount of information available regarding the
safety and effectiveness of the vaccine (Soon et al., 2015). The approach of verbally weighing
the pros and cons of the HPV vaccine with patients and presenting the HPV vaccine as optional
may be disadvantageous to increasing HPV vaccine coverage because parents who perceive the
HPV vaccine as optional were less likely to have their children vaccinated (Perkins et al., 2014).
A strength of many of these studies was that they are nationally representative. Although
physicians’ perspectives were obtained in Gilkey et al. (2015), the questions were generic.
Meaning, the questions are framed in a way that probes the physician to speak about patients in
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general. There were not any studies that asked physicians about how the patient’s characteristics,
other than gender and age, changed their approach. There is likely not a “one size fits all”
approach to recommending the HPV vaccine. There may be small adjustments physicians could
make when recommending the HPV vaccine based on the characteristics of the patient that
would be more effective and at increasing acceptance. This information could be useful to other
physicians trying to develop targeted approaches to recommending the HPV vaccine.
Additionally, since attitudes toward the HPV vaccine and social norms about its administration
are predictors of recommending the vaccine (Roberto et al., 2011), more research should focus
on these factors. To date, social norms have been used to develop an intervention study (Gilkey
et al., 2015), but attitudes toward the behavior have not. Furthermore, the response rate could
induce a form of bias (Roberto et al., 2011); for example, it is possible physicians who are
stronger advocates or adversaries of the HPV vaccine are opting to participate.
Barriers to Recommending the HPV Vaccine.
Compared to other vaccines, the HPV vaccine is more emotionally charged (Perkins et
al., 2014). In a nationally representative sample of physicians, participants reported on their
conversations about the HPV vaccine with their patients (Gilkey, Moss, et al., 2015). It was
revealed that these conversations were more negative than conversations about other vaccines
(Gilkey, Moss, et al., 2015). The belief that female patients’ parents would refuse the vaccine
was a barrier to physicians strongly recommending the vaccine (Daley et al., 2006). “I expect the
parents to refuse” was reported by 29% of physicians, who were not consistent recommenders of
the HPV vaccine, as one of the reasons he or she would not recommend the vaccine (Kepka et
al., 2012). Another study reported 24% of pediatricians and 25% of family practitioners, who
were 18 months post medical licensure, had experienced upset parents after offering their 11-12-
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year-old child(ren) a vaccine for an STI; however, this did not impact their likelihood to continue
recommending the vaccine (Daley et al., 2010). Demonstrating that newer, potentially younger
physicians, who may themselves have received the HPV vaccine, are more resilient to pushing
forward with the recommendation.
Physicians also spend more time talking about the HPV vaccine compared to Tdap and
meningococcal vaccine (Hughes et al., 2011). In a nationally representative sample of family
practitioners and pediatricians, physicians reported spending on average 3.7 minutes talking
about the HPV vaccine, which was significantly more than the Tdap (1.9 minutes) and
meningococcal vaccine (2.2 minutes) (Gilkey, Moss, et al., 2015). This longer duration of time
spent talking about the HPV vaccine may be in part be because physicians feel the need to
discuss STIs concurrently with the HPV vaccine (Daley et al., 2006). Nearly half of pediatricians
(42%) and family practitioners (53%) think it is necessary to discuss sexuality before
administering the HPV vaccine (Daley et al., 2010). No matter what the reason for spending
more time talking about the HPV vaccine compared to other vaccines, the result is problematic.
Physicians reported “the amount of time that is required to recommend the HPV vaccine” as a
barrier to recommending the vaccine were less likely to provide a strong recommendation
compared to those who did not see time as a barrier (Daley et al., 2010). “I don’t have enough
time to discuss [the HPV vaccine]” was cited by 47% of physicians who reported not being a
regular recommender of the HPV vaccine (Kepka et al., 2012). Finally, clinicians reported
reinforcing the benefits of early vaccination (i.e., prior to sexual debut) when recommending the
vaccine (Henninger et al., 2017). However, this creates another barrier for physicians because
some physicians are uncomfortable discussing sexuality with young patients (Henninger et al.,
2017) and believe parents of children aged 10- to 12-years are upset when a vaccine for an STI is
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recommended for their children (Daley et al., 2006). This may explain why in a national survey
of physicians, the knowledge that the HPV vaccine produces a stronger antibody response in
younger adolescents compared with adults was not associated with their HPV vaccine
recommendations (Allison et al., 2016).
Inappropriate Reasons for Not Recommending the HPV Vaccine.
Data from the Cervical Cancer Screening conveyed that only 53% of physicians made
recommendations consistent with all guidelines (Kepka et al., 2012). This data was collected
shortly after the FDA approval for the HPV vaccine, and therefore, it unlikely that it is still
representative of physicians today. Despite the CDC’s recommendation to vaccinate all children
11-12 years of age (Centers for Disease Control and Prevention., 2018), physicians sometimes
used extraneous factors to determine if a recommendation to receive the HPV vaccine was
needed. Physicians who had large patient bases on public health insurance were more likely to
strongly recommend the HPV vaccine compared to physicians who believed < 10% of their
patients received public health insurance (Daley et al., 2010). Yet, other research which
examined physicians’ recommendations on the individual level rather than examining the
entirety of the physician’s patients demonstrated the type of insurance a patient had did not
impact the likelihood that physicians would recommend the vaccine (Ojinnaka et al., 2017;
Vadaparampil et al., 2011).
Age is consistently used by physicians to determine appropriate recommendation timing
in a manner that is not always consistent with the age recommendations put forth by the CDC.
Despite the fact that nine years of age is the earliest age in which the vaccine is recommended,
physicians introduce the HPV vaccination at 11 years of age but do not strongly recommend it at
that age (Perkins et al., 2014). Among a nationally representative sample of 118 pediatricians
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and 104 family practitioners who were not regular recommenders of the HPV vaccine at wellness
visits, 38% of pediatricians and 28% of family practitioners indicated a reason for not
recommending the HPV vaccine is because they think the patient is too young (Kepka et al.,
2012). Nearly all of the providers (90%) in this study recommended the HPV vaccine to at least
some patients (Kepka et al., 2012). However, only 41% of physicians recommended it to females
aged 9-12 years (the age in which the CDC recommends receiving the HPV vaccine), while
nearly double (80%) the physicians recommended the vaccine to females aged 13-26 years
(Kepka et al., 2012). Finally, 21% of physicians recommended the HPV vaccine to females aged
27 years and older (Kepka et al., 2012). It is important to note, that Kepka et al., (2012) was
published before the new HPV vaccine recommendations when it was not approved for people
26 years of age or older. Further evidence of delayed HPV vaccine recommendations was
demonstrated in a study by Daley et al., (2010). In this study 78% of pediatricians and 65% of
family practitioners believed parents were more likely to vaccinate their 16-18-year-old children
compared to 11-12-year-olds; consequently, physicians were less likely to provide a strong
recommendation for the HPV vaccine to the parents of the younger children (Daley et al., 2010).
The average age of sexual debut in the United States is about 17 years of age, therefore waiting
till 16-18 years of age to receive the vaccine may be too late for preventing the transmission of
HPV (Magnusson et al., 2015; Planned Parenthood, 2011).
Age was not the only inappropriate tool used for decision making about recommending
the HPV vaccine. “The patient is already getting other vaccines at that visit” was reported by
35% of physicians as a reason not discussing the HPV vaccine (Kepka et al., 2012), Providers
expressed reluctance to give multiple shots at one visit (Perkins et al., 2014). Additionally,
providers occasionally recommended the vaccine based on their estimation of the patient’s
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sexual activity (Perkins et al., 2014). “I know the patient is not yet sexually active,” was cited by
54% of pediatricians and 35% of family practitioners who did not regularly discuss the HPV
vaccine as reasons for not discussing it (Kepka et al., 2012). From this data, it appears physicians
using age as an indicator of when to recommend the HPV vaccine, is a result of the lived
experiences of parents’ reactions to their child being recommended the HPV vaccine, their
assessment of the patient’s sexual experience, and the CDC guidelines.
Both of these studies examined the age of typically-developing patients (Daley et al.,
2010; Kepka et al., 2012). Women in the United States who have an intellectual disability (ID)
are often inaccurately viewed as asexual (Milligan & Neufeldt, 2001), even by their parents
(Stein & Kohut, 2015); which may result in these women missing this import primary
preventative behavior. As previously mentioned, parents already struggle to view their typicallydeveloping children as sexual beings who need the HPV vaccine. Therefore, this may be
exacerbated in women with an ID, whose parents may play a vital role in their health care for
their entire lives (National Council on Disability, 2019).
Intellectual Disabilities and the HPV Vaccine
In the last four to five decades, there has been a shift toward deinstitutionalizing people
with ID and an increase in efforts to integrate them into mainstream society (Metzel & Walker,
2001). With their integration into mainstream society, the life expectancy of people with an ID
increased and consequently are being diagnosed with chronic diseases, often associated with age,
such as cancer, at nearly the same rate as the general population (Hosking et al., 2016; Sullivan,
Hussain, Threlfall, & Bittles, 2004; Walker, 2015). So, what used to not be a health concern for
the ID population has now become a health concern. Since cervical cancer tends to be diagnosed
at a younger age than other cancers (American Cancer Society, 2018) this may be of particular
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concern for females with an ID. An increased focus on the prevention of cervical cancer in
women with an ID is needed.
Furthermore, routine methods to screen for cervical cancer are invasive and difficult to
complete in these women (Kavoussi et al., 2009). There are many barriers, such as cooperation
and physical difficulties in receiving pap smears for women with disabilities (Abells et al.,
2016). The detection of cervical cancer in women with ID may require special considerations or
methods of obtaining cervical cells (Kavoussi, Smith, Ernst, & Quint, 2009). In a sample
obtained from the NHIS (2000-2005), women with any type of disability were less likely to have
received a pap smear in the last year compared to women with no disability, but more likely to
have received a recommendation to receive a pap smear (Rivera Drew & Short, 2010).
Suggesting, these women are often choosing to forego this behavior, despite medical
professionals recognizing the importance of them receiving it. For this reason, primary
prevention via the HPV vaccine is important because the secondary preventative behavior for
early detection is invasive and underutilized. However, unlike pap smears, it is unknown if
physicians are recommending the primary preventative behavior associated with cervical cancer.
The most common route of transmission of HPV is through sexual contact (Centers for
Disease Control and Prevention, 2018b). Although often debated about ethics, agency, and
ability to understand and engage in sexual activity, women with ID do have desires to be
sexually active (Stein & Dillenburger, 2017). Unfortunately, these women also have a high risk
of becoming victims of sexual assault. In a nationally representative survey from the National
Intimate Partner and Sexual Violence survey for the year of 2010, women with a disability were
3.3 (95% CI =1.6-6.7) times more likely to have experienced rape than were women without a
disability (Basile et al., 2016). The World Health Organization estimates children with ID are 4.6
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times more likely to be a victim of rape than their peers without a disability (Hughes et al.,
2012). Although women with a disability were significantly less likely to have had a sex partner
in the last six months than women with no disability, 58.0% of women with a disability did have
a sexual partner within the last six months (Rurangirwa et al., 2006). In addition, it is estimated
4.9%-6.6% of children with an ID compared to 2.8% of children without a disability are sexually
abused with penetration before the age of 12 (Horner-Johnson & Drum, 2006). Thus, women
with ID may be exposed to the unwanted consequences of sexual activity, including an HPV
infection, via sexual coercion.
Beyond sexual coercion, women with ID engage in desired dyadic sexual activity as well.
In an ethnographic study of women with ID, 12 out of 14 had sexual experiences (Bernert &
Ogletree, 2013). In a survey of facilities housing less than or equal to 50% of clients with
profound mental retardation, facilitators were asked about the sexual behavior that occur
between clients in the facility (Gust et al., 2003). This study revealed heterosexual kissing was
reported by 95% of the facilitators, heterosexual intercourse between two adults by 70% of the
facilitators, same-sex intercourse between two males by 89% of the facilitators, and same-sex
behaviors between two females by 56% of the facilitators (Gust et al., 2003). Women with ID
expressed negative feelings about sex or had mixed feelings which were context-specific (e.g.,
married or not, in love or not), which drove them into abstinence even after sexual debut or
complete abstinence until marriage (Bernert & Ogletree, 2013).
It was common for women with ID to try to hide their sexual experience from their
parents or caretakers (Bernert & Ogletree, 2013). This may contribute to quantitative research
findings that parents of children with ID viewed their child as asexual and unlikely to engage in
sexual behaviors (Stein & Kohut, 2015). However, qualitative research demonstrates a parent’s
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beliefs about their child’s sexuality to be more complex. Interviews with parents of children with
ID revealed parents were heavily focused on their children acting on their sexual desires and
urges in a manner that defies social norms (e.g., masturbating in public) and their hygiene (e.g.,
hand washing after masturbation) (Ballan, 2012). Another qualitative study of parents with
children who have ID uncovered that parents recognized their children had urges and desires for
sexual activity but were mainly concerned about them becoming a victim to sexual exploitation
(Rehm et al., 2012). There were no parents in either study who mentioned the possibility of their
child becoming infected with an STI as a concern regarding their child’s engagement in sexual
activity. Suggesting, HPV may not be at the forefront of these parent’s concerns about their
child’s sexual health.
Differences in development may also contribute to parent’s apprehension about their
child with ID becoming sexually active. There are only slight differences in biological sexual
development between women with ID and typically developing women, with a slight (<1 year-2
year) delay in women with ID (Baidwan et al., 2014). However, their social skills are heavily
delayed creating a discrepancy between their biological sexual desires and the ability to
understand sexuality and make social connections with potential sexual partners (Murphy et al.,
2006). Parents seem to be aware of this incongruity between biological and social maturity and it
fuels their perspectives about their child with ID as a sexual being. For example, although
parents recognized their child had sexual desires, parents were ambivalent about their child’s
potential to engage in partnered sexual activity because of their child’s struggles to form
connections with their peers (Ballan, 2012).
Although conclusive data is lacking, it is unlikely people with ID are practicing safe sex
(Bernert & Ogletree, 2013; Servais, 2006). Even though women do recognize and associate sex
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with AIDS, safe sex practices regarding STIs and sexual health knowledge are poor in this
population (Bernert & Ogletree, 2013; Servais, 2006). Sexuality education about STIs was
associated with greater initiation of the HPV vaccine in typically-developing women (Bouza and
Hammig, under review). Therefore, the lack of appropriate sexuality education may be hindering
the uptake of the HPV vaccine in women with ID. However, since no data on their uptake of the
HPV vaccine coverage in the United States is available, it is impossible to say for certain.
To date, there is no research exclusively examining the HPV vaccine uptake in the ID
population in the United States. In Australia, people without an ID had a higher uptake of the
HPV vaccine compared to women with an ID (O’Neill et al., 2019). Nearly half of the people
with an ID initiated the HPV vaccine, and 39.5-44.1% completed the vaccine compared to 80.987.2% of the general population who initiated the HPV vaccine and 71.3-78.6% who completed
the HPV vaccine (O’Neill et al., 2019). In the United Kingdom, there was not a statistical
difference in HPV vaccine uptake between 14-year old females in the general population
compared to their counterparts with an ID (Emerson et al., 2019). It is unreasonable to assume
similar HPV vaccine coverage would be found in the United States. Australia, Canada, and the
UK are identified as having the most successful programs for HPV vaccine coverage (President’s
Cancer Panel, 2013). In Australia, the HPV vaccine is administered free of charge in school
(Cancer Council Victoria, 2019). In the UK, the HPV vaccine is also administered in schools,
which is where 94.4% of adolescents who are vaccinated received the HPV vaccine (Sheridan &
White, 2011). None of the previously described efforts in Australia or the UK are present in the
United States.
If the same macro-level efforts were made in the United States, it is possible the
outcomes regarding HPV vaccine coverage would result. A review article concluded, when the
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social norm was to receive the HPV vaccine, and when parent’s peers accepted the vaccine for
their children, parents were more likely to accept the vaccine for their own children (Brewer &
Fazekas, 2007). Furthermore, when schools required the HPV vaccine, this was a cue to action
for parents to have their child vaccinated (Brewer & Fazekas, 2007). However, until there are
macro-level changes in the United States, research initiatives that focus on working within the
parameters of the current administrative policies are needed to inform intervention research.
Additionally, there appears to be no research on the medical provider’s perceptions of the
sexuality of women with ID as it relates to their need to receive the HPV vaccine. This is a
particularly relevant topic considering these women’s recent increased risk of cancer (Sullivan et
al., 2004; Walker, 2015). parents viewing them as asexual (Stein & Kohut, 2015), and physicians
reluctance to recommend the HPV vaccine to dependents when the anticipated parental reaction
is negative (Daley et al., 2006; Kepka et al., 2012; Soon et al., 2015). Further, based on
qualitative research, parents appear to have a lack of recognition of STIs as a health risk to their
child with ID (Ballan, 2012; Rehm et al., 2012). Parents can play an active role in medical
decisions for their child with ID for the duration of their entire life (National Council on
Disability, 2019).
Preliminary analysis of nationally representative data revealed a cell size well below what
is considered acceptable for inferential analyses, suggesting a low uptake of the HPV vaccine in
women with ID. Consequently, this data cannot be used for quantitative analysis. Physicians are
uniquely positioned to help elucidate on multiple elements that impact the uptake of the HPV
vaccine in this population. Physicians can provide insight into factors they consider when
deciding whether to provide a recommendation for the HPV vaccine in this population.
Additionally, physicians can speak about their experiences of recommending the HPV vaccine to
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children with ID and their parents’ or caregivers’ reactions and questions about the vaccine.
Until now, physicians who treat people with ID have been ignored in this body of literature, and
therefore there is no research that has specifically sought to obtain physicians' attitudes,
experiences, and perspectives on this emerging public health concern. Although no research has
specifically evaluated whether physicians’ perceive people with an ID as sexual beings, a review
article concluded this population is often inaccurately labeled as asexual, suggesting physicians
may hold similar views (Milligan & Neufeldt, 2001).
Physicians have the unique perspective of both their medical opinions and expertise as
well as direct experience of what the concerns, questions, and responses parents have to their
child being recommended the HPV vaccine. For example, physicians understand the medical and
health reasons for receiving the HPV vaccine and but also serve as a resource for parents who
seek to obtain sexual health information for their child. As such, parents confide in and request
information from their physicians. This places physicians in a unique position to elaborate on not
only their own perspectives about the HPV vaccine, but also can share the questions and
comments they receive from parents. This information provided insight about parent’s feelings
toward the HPV vaccine for their female child with an ID through the provider's perspectives.
The second purpose of this study was to examine the physician’s experiences of
recommending the HPV vaccine. This included exploring the physician’s reasons for
recommending or not recommending the HPV vaccine to patients in this population. It also
included an exploration of the physician’s perceived importance of the HPV vaccine in this
population. Finally, physicians were asked about parental responses, questions, and concerns
after receiving a recommendation for their female child with ID receive the HPV vaccine.
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Method
Part One
Data Source
The data for was obtained from the 2017 National Health Interview Survey (NHIS). This
is a nationally representative dataset conducted by the National Center for Health Statistics. The
survey is a cross-sectional survey administered in the participant’s home and is conducted in
English or Spanish by trained personnel. The NHIS provides estimates of health indices, health
care utilization and access, and select health behaviors. Excluded from this survey are the
institutionalized population, U.S. citizens living abroad, and active-duty military. Commercial
address lists were used as the main source addresses, which was new for the NHIS as of 2016.
Previous years of the NHIS oversampled minority groups; however, as of 2016, this
oversampling procedure was removed. The NHIS uses a multistage, stratified sampling frame.
This requires the users of the data to employ a weight factor to produce nationally representative
estimates. The weighted estimates include only the civilian, noninstitutionalized household
population. This was a secondary analysis of data collected and approved under the auspices of
the U.S. Centers for Disease Control and Prevention and therefore was deemed exempt by the
University of Arkansas’s Institutional Review Board (appendix A).
Variables from the sample adult file panels of data were used. All analyses were run
using SPSS version 24 Complex Sampling. First, a plan file containing complex sample
specifications such as sample structure, estimation methods for each stage, and references to
required variables, such as sample weights was created and used for analyses. The sample for
this study was exclusive to women 18-26 years of age. In 2017, the recommendation to receive
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the HPV vaccine did not extend beyond 26 years of age and therefore providing justification for
the maximum age cut off in this study.
Measures
The following questions were asked during the NHIS interviews and were used as the
outcome variable in this study, “Have you ever received an HPV shot or vaccine?” The response
options were “yes” or “no.” If yes, then respondents were asked how old they were when they
received the vaccine. The following questions constituted predictor variables in set one (health
care utilization). For all of the following questions, response options were “yes” or “no”.
“During the past 12 months, have you seen or talked a doctor who specializes in women's health
(an obstetrician/gynecologist)?” “During the past 12 months, have you seen or talked to a general
doctor who treats a variety of illnesses (a doctor in general practice, family medicine, or internal
medicine)?” Due to limited cell size, a new variable was created to combine users of
naturopathic and homeopathic care services (CAM use). Women who had seen one or both
(naturopathic or homeopathic care provider) in the previous 12 months were coded as yes and
women who had not seen either in the previous 12 months were coded as no. Finally, in predictor
variable set one, the respondent’s concern about the cost of routine or normal health care was
assessed by the following item: “How worried are you right now about not being able to pay
medical costs for normal healthcare?” The response options were, “very worried”, “moderately
worried”, “not too worried”, or “not worried at all.”
The next set of questions referred to the characteristics of health care received and
formed predictor variable set two. Items included “How often did your health care providers ask
for your opinions or beliefs about your medical care or treatment? For example, what kind of
tests, procedures, or medications you prefer.” The response options were “always”, “most of the
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time”, “some of the time”, or “none of the time.” “How often were you able to see health care
providers who were similar to you in any of these [values, beliefs, culture] ways?” Response
options were “always”, “most of the time”, “some of the time”, or “none of the time.” “In
general, how satisfied are you with the health care you received in the past 12 months?” The
response options were, “very satisfied”, “somewhat satisfied”, “somewhat dissatisfied”, or “very
dissatisfied.” “How often were you treated with respect by your health care providers?” The
response options were “always”, “most of the time”, “some of the time”, or “none of the time.”
“How often did your health care providers tell or give you information about your health and
health care that was easy to understand?” The response options were “always”, “most of the
time”, “some of the time”, or “none of the time.”
Statistical Analysis
The sample for this study was exclusive to women 18-26 years of age and therefore the
subpop function for SPSS, as outlined by the NHIS, was used for all analyses. Crosstabs were
completed using unweighted data to ensure adequate cell size for statistical analyses. When cell
size was small (unweighted n < 30), response options were condensed into fewer categories or
removed from analyses (National Center for Health Statistics, 2008). Descriptive statistics of
weighted variables of interest were then analyzed. Next, four logistic regression models were
employed. Model one was a univariate logistic regression model to examine the relationship
between the first set of predictor variables and the initiation of the HPV vaccine. Model two was
also a univariate logistic regression model to examine predictor variable set two in association
with the initiation of the HPV vaccine.
Next, a multinomial model (model 3) was run using the following as the outcome
variables: never received the HPV vaccine (referent group), received the HPV vaccine between
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9-16 years of age or between 17-26 years of age. Predictor variable set one was examined in
relation to the outcome variables to determine if these variables demonstrated different
associations with females who received the vaccine before or after the national average age of
sexual debut. CAM use was not included despite being a variable in predictor variable set one
due to inadequate cell size.
Finally, a third univariate logistic regression model was run (model 4). The outcome
variables in this model were: never received the HPV vaccine (referent group) and received the
HPV vaccine between 17-26 years of age and the second set of predictor variables was used.
This model exclusively examined respondents aged 17-26 years because 17 years of age is when
there is an increase in patients independently presenting themselves at doctor’s appointments and
predictor variable set two was considered less relevant for individuals whose parents decided for
them to receive the HPV vaccine (Ford et al., 2014). In all four regression models, race/ethnicity
and region of the country of residence were included as a control variables.
Hypotheses
Model One.
1. Respondents who saw a GP, but not an OBGYN, in the previous 12 months will have
significantly higher odds of HPV vaccine uptake compared to respondents who did not
receive health care from a GP or an OBGYN in the previous 12 months.
2. Respondents who saw an OBGYN, but not a GP, in the previous 12 months will have
significantly higher odds of having received the HPV vaccine compared to respondents
who did not receive care from a GP or an OBGYN in the previous 12 months.
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3. Respondents who saw a GP and an OBGYN in the previous 12 months will have
significantly higher odds of HPV vaccine uptake compared to respondents who did not
receive care from a GP or an OBGYN in the previous 12 months.
4. Respondents who saw a CAM provider in the previous 12 months will have significantly
lower odds of HPV vaccine uptake compared to respondents who did not see a CAM
provider in the previous 12 months.
5. Respondents who were not all worried or not too worried about the cost of routine health
care will have significantly higher odds of HPV vaccine uptake compared to respondents
who were very worried. There will be no differences between those who were very
worried and those who were moderately worried.
Model Two.
1. Respondents who saw a medical provider who asked about their opinions and beliefs
(some of the time, most of the time, always) will have significantly greater odds of HPV
vaccine uptake compared to none of the time.
2. Respondents who reported feelings of being treated with respect by their medical
provider all of the time or most of the time will have significantly higher odds of HPV
vaccine uptake compared to those who reported some or none of the time.
3. Respondents who were ever able to see a physician who shares the same culture as them
(some of the time, most of the time, always) will have significantly higher odds of
receiving the HPV vaccine compared to respondents who never saw a physician who
shares the same culture as them.
4. Participants whose physicians provided them with information they understood most of
the time or always will have significantly higher odds of receiving the HPV vaccine
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compared to participants whose physician only provided them with information they
understood some or none of the time.
5. Respondents who were very satisfied or satisfied with their health care will have
significantly higher the odds of having received the HPV vaccine compared to those who
were dissatisfied.
Model Three.
1. Compared to respondents who did not receive care from a GP or an OBGYN,
respondents who received care from an OBGYN, but not a GP, will be have significantly
higher odds of HPV vaccine receipt between the ages of 17-26 years of age, but not for
those who received the vaccine between 9-16 years of age.
2. Compared to respondents who did not receive care from a GP or an OBGYN, those who
received care from a GP only will have significantly higher odds of HPV vaccine receipt
between 9-16 years of age and 17-26 years of age.
3. Compared to respondents who did not receive care from a GP or an OBGYN,
respondents who received care from a GP and an OBGYN will have the significantly
higher odds of HPV vaccine uptake between 9-16 years of age and 17-26 years of age.
4. Cell size for CAM use was too small to justify including it in the multinomial model.
5. Respondents who were not all worried or not too worried about the cost of routine health
care will have significantly higher odds of HPV vaccine uptake between the ages of 1726 years but there will be no association for those who received it between 9-16 years of
age compared to respondents who were very worried. There will be no differences in
either age group between respondents who were very worried and respondents who were
moderately worried.
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Model Four.
1. Respondents who saw a medical provider who asked about their opinions and beliefs
(some of the time, most of the time, always) will have significantly greater odds of HPV
vaccine uptake between 17-26 years of age (versus never receiving the HPV vaccine)
compared to respondents whose physicians never asked about their opinions and beliefs.
2. There will be a significant increase in the odds of HPV vaccine uptake between 17-26
years of age (versus never receiving the HPV vaccine) in respondents who saw a
physician who always or most of the time treats them with respect compared to some or
none of the time.
3. Respondents who ever see a physician who shares the same culture as them (some of the
time, most of the time, always) will have significantly higher odds of receiving the HPV
vaccine between 17-26 years of age (versus never receiving the HPV vaccine) compared
to respondents who never see a physician who shares the same culture as them. This
question excluded individuals who indicated it was unimportant for them to see a
physician who shares the same culture as them.
4. Respondents whose physicians provided them with information they understood most of
the time or always will have significantly higher odds of receiving the HPV vaccine
between 17-26 years of age (versus never receiving the HPV vaccine) compared to
participants whose physicians only provided them with information they understood
some or none of the time.
5. Respondents who were somewhat satisfied or very satisfied with their health care will
have significantly higher odds of HPV vaccine uptake between 17-26 years of age
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(versus never receiving the HPV vaccine) compared to those who were dissatisfied with
their health care.
Part Two
Institutional Review Board approval was obtained (appendix B). In order to understand
the subjective experiences, an open-ended online cross-sectional survey using Qualtrics Survey
Panels was used. Physicians are uniquely positioned to elucidate about the HPV vaccine uptake
in females with an intellectual disability (ID). For example, they know what factors they consider
when deciding about providing a recommendation to receive the HPV vaccine and can provide
insight about their perceptions of the medical importance and need of the HPV vaccine in this
population. In addition, physicians can provide information about the parent’s reactions,
questions, and concerns regarding their child receiving the HPV vaccine. This study sought to
answer the following research questions.
RQ1: What factors do physicians consider when determining whether to recommend the HPV
vaccine?
RQ2: How do physicians describe their experiences of recommending the HPV vaccine to
parents of children with ID (including physicians’ perceptions of parents’ reactions, concerns, or
questions upon receiving this recommendation)?
RQ3: Why do physicians believe the HPV vaccine is important specifically for females with an
ID?
RQ4: Do physicians feel confident they can convince patients with an ID to accept the HPV
vaccine and what strategies have they used to accomplish that.
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Participants
This was be quota and convenience sample (Taherdoost, 2016). Inclusion criteria
included the completion of a medical residency in one of the following: pediatrics, obstetrics and
gynecology, or family practice, experience treating patients who have an ID, 26 years of age or
older, and currently practicing medicine in United States.
Protocol
An online survey was employed for this study. Qualifying participants first completed a
demographic survey which included the following information: age, gender, region of the
country in which he or she practices medicine, type of practice (private, public, teaching hospital,
not for profit), medical specialty, the number of years practicing medicine, and if their place of
employment has an HPV vaccine policy (e.g., patients are required to have the HPV vaccine to
be seen by the physicians or medical providers at their clinic). Next, participants were asked if
they have ever recommended the HPV vaccine to female patients (without ID and with ID).
Based on their response regarding their HPV vaccine recommendations to female patients with
an ID, the participants were presented with one of two sets of open-ended questions. For
participants who indicated they have recommended the HPV vaccine to females with an ID, the
following questions were presented:
1. What factors do you consider when deciding about whether to recommend the HPV
vaccine to female patients with an intellectual disability?
2. Could you describe common responses from female patients with an intellectual
disability or their caregivers that you have encountered while recommending the HPV

59

vaccine to them? For example, what were the patient's, parent's, or caregiver's questions,
comments, concerns, or emotional responses?
For participants who indicated they have never recommended the HPV vaccine to females with
an ID, the following questions were presented.
1. What factors do you consider when deciding/choosing not to recommend the HPV
vaccine to female patients with an intellectual disability?
2. Have previous experiences discussing matters of sexual health or recommending the
HPV vaccine to females with intellectual disabilities led you to not recommend the HPV
vaccine to female patients with an intellectual disability (answered with yes or no)? If yes
was selected, then participants were asked to elaborate on those experiences.
Irrespective of whether the participant has ever recommended the HPV vaccine to their female
patients with an ID, the following questions were presented.
1. What level of importance do you give the HPV vaccine in females with an ID (a Likert-

type question with the following responses)? Which was followed up with the open-ended
question, why do you give it that level of importance?
2. Do you believe you could convince parents or caregivers of female patients with an

intellectual disability to consent to their child receiving the HPV vaccine? Why or why
not?
a. If yes, participants were asked what strategies they used to convince patients or
parents/caregivers to consent to the patient receiving the vaccine.
Data Analysis
The data were analyzed through an inductive process using content analysis which is
commonly used when trying to understand health care professionals’ experiences (Vaismoradi et
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al., 2013). The procedure for developing themes was guided by Perkins & Clark, (2013) and Elo
and colleagues (2014). The procedures used to prepare the data for multiple coders to obtain
interrater reliability of the themes was guided by Marcantonio & Jozkowski, (2020). Quirkos
software was used to organize the data. Each question (that was asked of participants) was
entered into Quirkos separately and was analyzed independently from the other questions. First
the lead researcher familiarized herself with the data from each question. Next, the lead author
identified themes that emerged from each question. Next, themes were condensed where
appropriate and subthemes were formed from broader themes. When necessary, themes were
revised as needed. After the lead researcher identified all of the themes that emerged, the second
researcher, then reviewed the codes and themes and made adjustments as they saw necessary.
Finally, a codebook was developed. The codebook broke down each question and each theme
and subtheme. The codebook gave a description of each code (appendix C). Three researchers
were trained by the lead researcher and for each question, two coders independently reviewed the
codebook and description of each theme and then coded the data. Interrater reliability was run
using Cohen’s kappa and a minimum of 0.80 was necessary to be considered reliable (Braun &
Clarke, 2012). When such congruency between coders was not achieved, the primary
investigator provided the tie-breaker code.
When a participant gave multiple responses to a single question, their response was
broken up thematically. Therefore, some individual’s data are represented multiple times in each
question to reflect their entire response. For example, if a participant said, “I think the HPV
vaccine is important for females with an ID because they have a risk high of being sexually
assaulted and because they do not understand the consequences of sexual activity” then that
statement was broken down into two parts 1) risk of sexual assault and 2) not understanding the
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consequences of sexual activity. Descriptive information such as age, gender, region of the
country in which the physician practices medicine, years practicing medicine, and medical
specialty were analyzed in SPSS version 24. Additionally descriptive information such as has
ever recommended the HPV vaccine to females with/without an ID, perceived importance of the
HPV vaccine in females with an ID, work place policy requiring patients to have the HPV
vaccine, and sense of obligation to convince parents of or the female patient with an ID to
consent to receiving the HPV vaccine were also analyzed using SPSS version 24.
Ethical Considerations
Credibility.
The creative nature of qualitative analysis requires checks to ensure credibility (Patton,
1999). Credibility was addressed by the inclusion of data triangulation, methodical reporting in
sufficient detail, and transparency about my experience with qualitative research (my first time
collecting open-ended data) and the study topic (HPV vaccine) (Noble & Smith, 2015; Patton,
1999). Data perspective triangulation was achieved by collecting data from a sample of
OBGYNs, pediatricians, and family practitioners. My personal experience, connections, and
beliefs on the topic of interest in qualitative research was addressed to increase the credibility of
the researcher (Patton, 1999). I have no personal experience with the physician’s task of
recommending the HPV vaccine to patients, parental consent to children receiving the vaccine,
or with the health care of persons with an ID. This lack of experience reduced preexisting biases
but also introduced potential sources of error.
As a supporter of the HPV vaccine, this may have bias my interpretation of the data
(Patton, 1999). Funding sources can introduce bias into the results. Although this study received
funds, the funding sources (The Department of Health, Human Performance, and Recreation at
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the University of Arkansas and the Doug Kirby Adolescent Sexual Health Research Grant) did
not influence the interpretation of the findings (Patton, 1999).
Triangulation.
Data perspective triangulation was used in this study. Triangulation of data perspectives
involved gathering data from multiple sources to obtain diverse perspectives (Cohen & Manion,
1997; Ziyani et al., 2004). To remain consistent with previous literature and theoretical
relevance, the three primary care medical specialties that currently dominate the samples of
previous research studies were examined. There are mixed suggestions for adequate sample size.
One review study suggested between six and ten participants (Marshall et al., 2013) and a review
study indicates the range in the literature was between seven and eighty-nine participants
(Mason, 2010). The desired population was highly specific. The sample size obtained in this
study (N=51) is 40% larger than the sample size used in a previous study in which the
researchers conducted in-depth interviews, but with a less specific sample of health care
providers (physicians and mid-level medical providers) about their perceptions of parent’s
attitudes about the HPV vaccine (Perkins & Clark, 2013)
Dependability.
Dependability in qualitative research is thought to be the analogous term to reliability in
quantitative research (Lincoln & Guba, 1985). Joppee (2000) defined reliability as the extent to
which results are consistent over time (as cited by, Golafshani, 2003). The results of this study, if
repeated, would not be consistent over time. Vaccines are divisively constructed by society as
inherently protective or unsafe. As society is ever-changing, so will people’s perceptions of
vaccines. HPV is inextricably linked to sexuality, further enhancing the ever-changing
perceptions of the HPV vaccine. Additionally, as the HPV vaccine is a relatively new medical
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intervention, it is likely particularly vulnerable to changing perspectives from society. The
purpose of this study was to provide information about the current status of the HPV vaccine in
this population and provide insight for future researchers to build upon this topic.
Confirmability.
Confirmability refers to repeated documentation of the observed evidence (Morse, 1994).
Multiple coders were used to code the final data to obtain interrater reliability. Interrater
reliability was described previously in the procedures section.
Transferability.
Transferability refers to the ability of the results to have an application to sites or
situations outside the scope of the study. This study was not meant to be transferable outside of
the scope of females with ID living in the United States. Further, this study was not meant to be
transferable to other cultures that have different methods for increasing HPV vaccine coverage.
Nor was the study meant to be applicable to vaccines other than the HPV vaccine. Three
methods were employed to maintain transferability. The first was to focus on the typical situation
(Slevin & Sines, 2000), rather than the outlier situation. Secondly, data was obtained from
multiple primary care specialties (Slevin & Sines, 2000). Third, a systematic approach to
developing the study methodology was used via completing a literature review to identify the
gaps in the literature (Slevin & Sines, 2000). A systematic approach to analyzing the data further
enhanced transferability.
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Receiving care from a general medical provider but not an OBGYN is associated with HPV
vaccine uptake
Abstract
The purpose of this study was to examine characteristics of the patient-provider relationship, the
reception of health care, and concern about the cost of routine health care with HPV vaccine
uptake in a nationally representative sample of females. Data came from the National Health
Interview Survey (2017) and were limited to females aged 18-26 years. Three univariate logistic
regressions were employed to examine the relationships between HPV vaccine uptake (yes or
no) and characteristics of the patient-provider relationship, the reception of health care, and
being concerned about the costs of routine health care. One multinomial logistic regression was
run to examine the reception of health care and concerns about the costs of routine health care
amongst respondents who received the HPV vaccine between 9-16 and 17-26 years of age,
compared to respondents who never received the vaccine. The univariate logistic regression and
multinomial logistic regression (for those who received the vaccine between 9-16 years of age)
revealed similar patterns of association. Those analyses revealed that compared to respondents
who received no health care, respondents who received care exclusively from a general medical
provider (GP) had higher odds of vaccine uptake, respondents who received care from an
OBGYN and a GP had even higher odds of HPV vaccine uptake. There was not an increase in
the odds of HPV vaccine uptake in respondents who received care exclusively from an OBGYN.
Receiving care from a GP or an OBGYN was not associated with vaccine initiation between 1726 years of age. Neither being concerned about the costs associated with receiving routine health
care nor characteristics of the patient-provider relationship was associated with HPV vaccine
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uptake. Receiving care from a GP was associated with greater odds of HPV vaccine uptake; but,
receiving care exclusively from an OBGYN was not.
Keywords: Health care providers, Primary health care, HPV vaccine, Cancer prevention
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Human papillomavirus (HPV) is spread through sexual contact and is pervasive amongst
sexually active persons (National Center for HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention, 2019). Each year 14 million people become newly infected with HPV (Center for
Disease Control and Prevention, 2017). HPV is responsible for nearly all cases of cervical
cancer, 90% of anal cancers, 65% of vaginal cancers, 70% of oropharyngeal cancers, and 50% of
all vulvar cancers (Centers for Disease Control and Prevention, 2018). Consequently, HPV
contributes to over 30,000 new cancer cases each year (Centers for Disease Control and
Prevention, 2018).
Despite a national health priority to increase the coverage of the HPV vaccine to 80% by
2020, estimates indicate that roughly half of all female adolescents are currently vaccinated
(Healthy People, 2014; Walker et al., 2017). Meaning this goal was not achieved, and increasing
HPV vaccine coverage in adolescents will continue to be a national health priority. The
President’s Cancer Panels (2013) identified three reasons for suboptimal uptake: missed clinical
opportunities, low acceptance of the HPV vaccine, and accessibility of the vaccine (President’s
Cancer Panel, 2013).
Missed clinical opportunities are the number one reason for low HPV vaccine coverage
in the United States (President’s Cancer Panel, 2013). On the most basic level, physically
visiting a health care provider is required to receive recommendations regarding care. In females,
wellness visits with a medical provider are routine until the age of 16 (Rand & Goldstein, 2018),
meaning adolescents who do not receive the HPV vaccine before the age of 16 will have fewer
opportunities to receive a recommendation to obtain the HPV vaccine.
There is an additional barrier for women to receive the HPV vaccine after the age of 16.
There is an increase in patients presenting themselves at medical appointments without the
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supervision of a parent or legal guardian at the age of 17 years (Ford et al., 2014). The laws
regarding the age of consent to the HPV vaccine without a legal guardian vary by state (National
Conference of State Legislatures, 2018). Previously, researchers reported between 30%-50% of
physicians would not vaccinate a 17-year-old at their clinic without their parent’s consent (Ford
et al., 2014). However, that also implies that between 50%-70% of physicians may be willing to
vaccinate a 17-year-old without a legal guardian’s consent. Consequently, some adolescents,
who do not receive the vaccine at or before 16 years of age, will have to wait until they turn 18 to
receive the vaccine. As the average age of sexual debut in the United States is about 17 years of
age, this is problematic for the prevention of oncogenic serotypes of HPV infections (Planned
Parenthood, 2011).
Once a person seeks health care, the patient must receive a recommendation from a
physician to obtain the HPV vaccine (Rosenthal et al., 2011) and subsequently, the patient
adheres to that recommendation. There is a robust body of literature examining factors associated
with patient adherence to physicians’ recommendations. For example, the following are all
linked to increased patient adherence to physician’s recommendations: physicians using
comprehensible language (Martin et al., 2005), physicians respecting or sharing the patient’s
culture, values, beliefs or opinions (Newell & Jordan, 2015; Ohana & Mash, 2015), and patient
satisfaction with health care.(Bogart et al., 2004; Taylor et al., 2016). Nevertheless, none of these
factors have been examined in association with HPV vaccine uptake.
The type of care provider may also impact HPV vaccine uptake. Previous literature has
focused on pediatricians, gynecologists, and family practitioners. Not present in the current body
of literature are complementary and alternative medicine (CAM) providers. It is important to
consider these providers for two reasons. Firstly, in recent years, the use of CAM care has
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increased in the United States, and 4 out of 10 adults have sought this type of care (National
Center for Complementary and Integrative Health, 2017). Secondly, examples of CAM include
naturopathic and homeopathic medicine (National Center for Complementary and Integrative
Health, 2017), and these practitioners often propagate rhetoric consistent with the vaccinehesitant culture (Caulfield et al., 2017). Consumers of CAM report a fear of vaccines and reject
their use (Tissot et al., 2007). Children who have seen a CAM provider are four times less likely
to receive the influenza vaccine compared to children who have never seen a CAM provider
(Bleser et al., 2016; Salmon et al., 2005). However, it is unknown if there is an association
between CAM utilization and receiving the HPV vaccine.
The purpose of this study was to examine women’s health care use and characteristics of
their patient-provider relationship (that have been previously associated with adherence to
physician’s recommendations), and concerns about the cost of routine health care in association
with their HPV vaccine uptake. The second purpose of this study was to determine if these
predictor variables demonstrated different associations between females who initiated the HPV
vaccine before the national average age of sexual debut in the United States (9-16 years) or after
the national average age of sexual debut, but within the FDA approved age range for the year
2017 (17-26 years).
Method
The data came from the 2017 National Health Interview Survey (NHIS). The NHIS is a
nationally representative dataset conducted by the National Center for Health Statistics. The data
were collected and approved under the auspices of the U.S. Centers for Disease Control and
Prevention and were identified as exempt by the authors’ IRB. The survey was administered in
the participant’s home and was conducted in English or Spanish by trained personnel. The NHIS
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provides estimates of health indices, health care utilization and access, and select health
behaviors. Excluded from this survey were the institutionalized population, U.S. citizens living
abroad, and active-duty military. The NHIS used a multistage, stratified sampling frame, and
therefore a weight factor was used to produce nationally representative estimates.
The sample adult file panels of data were used. All analyses were run using SPSS version
24 Complex Samples. First, a plan file containing complex sample specifications such as sample
structure, estimation methods for each stage, and references to required variables (i.e., sample
weights) was created. The plan file was used for completing analyses. The sample for this study
was exclusive to women 18-26 years of age and therefore the subpop function for SPSS, as
outlined by the NHIS, was used for all analyses. In 2017, the recommendation to receive the
HPV vaccine did not extend beyond 26 years of age and therefore justifying the maximum age
cut off in this study. The sample was limited to females because females and males are not
socialized equally to the reception of urogenital care. (Smith et al., 2006).
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Measures
Table 1.
Complete list of predictor and outcome variables.
Question
Response option
Outcome variables
Have you ever received an HPV shot or vaccine?
Yes or no
At what age did you receive the vaccine
Open-ended
Predictor variable set one: Primary health care reception and affordability
During the past 12 months, have you seen or talked to a
Yes or no
doctor who specializes in women’s health (an
obstetrician/gynecologist)?
During the past 12 months, have you seen or talked to any a Yes or no
general doctor who treats a variety of illnesses (a doctor in
general practice, family medicine, or internal medicine)?
How worried are you right now about not being able to pay Very worried, moderately
medical costs for normal healthcare?
worried, not too worried, or not
worried at all.
A new variable was created to combine users of
Yes or no
naturopathic or homeopathic care services within the
previous 12 months.
Predictor variable set two: Patient-provider relationship
How often did your health care providers ask for your
Always, most of the time, some
opinions or beliefs about your medical care or treatment?
of the time, or none of the time
For example, what kind of tests, procedures, or medications
you prefer.
How often were you able to see health care providers who
always, most of the time, some
were similar to you in any of these [values, beliefs, culture] of the time, or none of the time
ways?*
In general, how satisfied are you with the health care you
very satisfied, somewhat
received in the past 12 months?
satisfied, somewhat dissatisfied,
or very dissatisfied
How often were you treated with respect by your health
Always, most of the time, some
care providers?
of the time, or none of the time
How often did your health care providers tell or give you
always, most of the time, some
information about your health and health care that was easy of the time, or none of the time
to understand?
Note. *This question was only asked to respondents who had previously indicated during the
survey that it was important to them to receive care from a physician who shared the same
culture as them.
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Statistical Analysis
Crosstabs using unweighted data were used to examine cell size. When cell size was
small (unweighted n < 30), response options were condensed into fewer categories (National
Center for Health Statistics, 2008). Descriptive statistics of weighted variables of interest were
analyzed. A univariate logistic regression model (model 1) was run to examine the association
between predictor variable set one and HPV vaccine uptake (yes or no). A second univariate
logistic regression model (model 2) was conducted to examine the association between predictor
variable set two and HPV vaccine uptake (yes or no). Consequently, model 2 was limited to only
those who received health care in the previous 12 months.
Next, a multinomial model (model 3) was run using the following as the outcome
variables: never received the HPV vaccine (referent group), received the HPV vaccine between
9-16 years of age or between 17-26 years of age. Predictor variable set one was examined in
relation to the outcome variables to determine if these variables demonstrated different
associations with females who received the vaccine before or after the national average age of
sexual debut. CAM use was not included despite being a variable in predictor variable set one
due to inadequate cell size.
Finally, a third univariate logistic regression model was run (model 4). The outcome
variables in this model were: never received the HPV vaccine (referent group) and received the
HPV vaccine between 17-26 years of age and the second set of predictor variables was used.
This model exclusively examined respondents aged 17-26 years because 17 years of age is when
there is an increase in patients independently presenting themselves at doctor’s appointments and
predictor variable set two was considered less relevant for individuals whose parents decided for
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them to receive the HPV vaccine (Ford et al., 2014). In all four regression models, race/ethnicity
and region of the country of residence were included as a control variable.
Results
The average age of the sample was 22.0 ± 0.1 years and just over half of the participants
(52.7%) had received the HPV vaccine (Table 2). Of those who received the HPV vaccine,
62.8% received the HPV vaccine between the ages of nine and 16 years, 21.0% received the
HPV vaccine between the ages of 17-26 years of age, and 16.2% either received the HPV
vaccine when they were younger than 9 years of age or did not know when they received the
vaccine. The majority of the sample was white/Caucasian (75.0%), followed by Black/African
Americans as the second-largest race/ethnicity group (Table 2). Nearly 25% of the sample had
not seen an OBGYN or a general medical provider (GP) in the previous 12 months (Table 3),
and only 2.3% of the sample received CAM care in the previous 12 months. Full descriptive
statistics can be found in Tables 2-4.
In model one (Table 5), after controlling for race/ethnicity and region of the country in
which respondents live, respondents who only received care from an OBGYN were no more
likely to have received the HPV vaccine compared to respondents who did not receive any health
care (OR=1.1, 95% CI=0.7-1.8). However, respondents who saw a GP, but not an OBGYN, did
have slightly higher odds of HPV vaccine reception compared to respondents who did not
receive any health care (OR=1.6, 95% CI=1.1-2.3). Furthermore, respondents who saw both a
GP and an OBGYN had the highest odds of HPV vaccine reception compared to those who did
not see any medical provider (OR=2.1, 95% CI=1.4-3.1). The cell size for females who used
CAM and who received the HPV vaccine was below the cell size threshold (unweighted n=22)
but was still included in the model because it is a novel variable to this literature. However,
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interpretation of this variable requires caution as estimates may be lacking precision. CAM use
was not associated with the uptake of the HPV vaccine (OR=1.1, 95% CI=0.5-2.5). Finally, in
model one, there was no association between respondents who were very worried about the cost
of routine health care and those who were moderately worried (OR=0.8, 95% CI=0.4-1.4), not
too worried (OR=1.5, 95% CI=0.8-2.6), or not at all worried (OR=1.1, 95% CI=0.6-1.9).
After controlling for race/ethnicity and region of the country in which the respondent
lived, none of the variables in model two (Table 5) were significant. Compared to respondents
whose physicians never asked them about their opinions and beliefs, respondents whose
physicians asked them about their opinions and beliefs some of the time (OR=1.3, 95% CI=0.92.1), most of the time (OR=1.2, 95% CI=0.8-1.9), or always (OR=1.4, 95% CI=0.8-1.7) did not
have greater odds of HPV vaccine uptake. Furthermore, there were no differences in the odds of
HPV vaccine uptake between respondents whose medical providers treated them with respect
some or none of the time and whose physicians respected them most of the time (OR=1.2, 95%
CI=0.5-2.8) or always (OR=1.3, 95% CI=0.6-2.8). Regarding respondents who reported it was
important to them to see a physician who shared a similar culture, there were no differences in
HPV vaccine uptake between those who never saw a physician who shared the same culture as
them and those who did some of the time (OR=1.6, 95% CI=0.5=0.8-3.2), most of the time,
(OR=1.3, 95% CI=0.7-2.6) or always (OR=1.7, 95% CI=0.9-3.3). There were no differences in
HPV vaccine uptake between respondents who reported their physicians provided
understandable information to them some or none of the time compared to most of the time
(OR=1.1, 95% CI=0.6-1.9), or always (OR=1.1, 95% CI=0.7-1.8). Lastly, in model two, there
were no differences in the odds of HPV vaccine uptake between those who were dissatisfied with
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their health care compared to those who were somewhat satisfied (OR=0.9, 95% CI=0.5-1.7) or
very satisfied (OR=1.2, 95% CI=0.6-2.3).
After controlling for race/ethnicity and region of the country in which the respondent
lived in the multinomial logistic regression (model 3; Table 6), receiving care exclusively from
an OBGYN was not associated with HPV vaccine reception between 9-16 years of age or 17-26
years of age (OR=1.4, 95% CI=0.8-2.5; OR=1.0, 95% CI=0.5-2.2. respectively) compared to
those who did not see a GP or an OBGYN. However, respondents who received care exclusively
from a GP had higher odds of HPV vaccine reception between 9-16 years of age compared to
respondents who did not receive care from a GP or an OBGYN (OR=2.0, 95% CI=1.3-3.3); but,
this was not the case for respondents who received the HPV vaccine between 17-26 years of age
(OR=1.2, 95% CI=0.6-2.3). Respondents who received care from a GP and an OBGYN had
higher odds of HPV vaccine reception between 9-16 years of age compared to respondents who
did not receive care from a GP or an OBGYN (OR=2.9, 95% CI=1.8-4.7); again, the same
association was not revealed in respondents who received the HPV vaccine between 17-26 years
of age (OR=1.7, 95% CI=0.9-3.1). Finally, in model three, compared to respondents who were
very worried about the cost of health care, respondents did not have higher odds of HPV vaccine
reception between 9-16 or 17-26 years of age who were not at all worried (OR=1.4, 95% CI=0.72.7; OR=0.7, 95% CI=0.3-1.5, respectively), not too worried (OR=1.7, 95% CI=0.9-3.3;
OR=1.0, 95% CI=0.4-2.2, respectively), or moderately worried (OR=0.8, 95% CI=0.4-1.6;
OR=0.7, 95% CI=0.4-1.7, respectively) (Table 6).
In model four, the univariate logistic regression revealed no significant associations
between the variables in predictor variable set two and receiving the HPV vaccine between 17-26
years of age (see Table 7 for each odds ratio and its 95% corresponding confidence interval).
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Table 2.
Descriptive data for outcome and control variables (weighted N=18,843,655)
N (%)
M ± SD
Ever received the HPV vaccine
Age (years)
22.0 ± 0.1
No
8,167,291 (47.3)
Yes (all)
9,098,876 (52.7)
9-16 years of age
5,713,633 (62.8)
17-26 years of age
1,909,072 (21.0)
Other
1,476,171 (16.2)
Race
White/Caucasian
14,090,753 (75.0)
Black/African American
2,902,126 (15.5)
AIAN
326,902 (1.7)
Asian
971,778 (5.2)
Multi-race
484,748 (2.6)
Region of the country
Northeast
3,582,206 (19.0)
Midwest
4,144,069 (22.0)
South
6,522,311 (34.6)
West
4,595,069(24.4)
*Other indicates respondents who received the HPV vaccine before the age of nine years,
refused to answer the question, and did not know how old they were when they received the
HPV vaccine.
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Table 3.
Descriptive statistics for predictor variables set one
N (%)
Health care use
No health care received
4,541,195 (24.4)
OBGYN only
2,285,226 (12.3)
GP only
6,203,749 (33.4)
OBGYN and GP
5,566,114 (29.9)
CAM user
Yes
431,763 (2.3)
No
18,411,892 (97.7)
Worried about the cost of health care
Very worried
1,564,061 (8.5)
Moderately worried
2789167 (15.1)
Not too worried
4,799,601 (26.0)
Not worried at all
9,286,920 (50.4)
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Table 4.
Descriptive statistics for the predictor variable set two
N (%)
Provider asked about opinion/beliefs
Always
Most of the time
Some of the time
None of the time
Treated with respect by the medical provider
Always
Most of the time
Some or none of the time
Physician shares culture
Always
Most of the time
Some of the time
None of the time
Physician provides information that is easy to understand
Always
Most of the time
Some or none of the time
Satisfied with health care
Very satisfied
Somewhat satisfied
Somewhat/very dissatisfied

2,371,872 (32.9)
2,285,029 (31.7)
1,579,714 (21.9)
964,171 (13.4)
10,841,378 (79.5)
2,182,978 (16.0)
619,139 (4.5)
2,806,872 (33.7)
2,596,572 (31.1)
1,863,514 (22.3)
1,073,078 (12.9)
10,851,647 (68.4)
3,863,124 (24.3)
1,161,617 (7.3)
11,534,959 (68.9)
4,467,544 (26.7)
746,189 (4.5)
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Table 5.
Models one and two: Factors associated with the receipt of the HPV vaccine
Model 1
Model 2
OR
95% CI
OR
95% CI
Health care
No health care
1.0
OBGYN only
1.1
0.7-1.8
GP only
1.6
1.1-2.3
OBGYN and GP
2.1
1.4-3.1
CAM use
No
1.0
Yesa
1.1
0.5-2.5
Worried about the cost of routine health care
Very worried
1.0
Moderately worried
0.8
0.4-1.4
Not too worried
1.5
0.8-2.6
Not at all worried
1.1
0.6-1.9
Provider asked about opinion/beliefs
None of the time
1.0
Some of the time
1.3
0.9-2.1
Most of the time
1.2
0.8-1.9
Always
1.4
0.8-1.7
Treated with respect by their medical provider
Some or none of the time
1.0
Most of the time
1.2
0.5-2.8
Always
1.3
0.6-2.8
Physician shares culture
None of the timea
1.0
Some of the time
1.6
0.8-3.2
Most of the time
1.3
0.7-2.6
Always
1.7
0.9-3.3
Physician provides information that is easy to understand
Some or none of the time
1.0
Most of the time
1.1
0.6-1.9
Always
1.1
0.7-1.8
Satisfied with health care
Dissatisfied
1.0
Somewhat satisfied
0.9
0.5-1.7
Very satisfied
1.2
0.6-2.3
a
Note. Denotes that sample size was just below the what is deemed accepted for inferential
analyses, respondent seeing a physician that shares the same culture as them (n=29) and seeing a
CAM provider (n=22).
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Table 6.
Multinomial logistic regression model three
9-16 years of age
OR
95% CI

17-26 years of age
OR
95% CI

Health care
No health care
1.0
1.0
OBGYN only
1.4
0.8-2.5
1.0
GP only
2.0
1.3-3.3
1.2
OBGYN and GP
2.9
1.8-4.7
1.7
Worried about the cost of routine health care
Very worried
1.0
1.0
Moderately worried
0.8
0.4-1.6
0.7
Not too worried
1.7
0.9-3.3
1.0
Not at all worried
1.4
0.7-2.7
0.7
Note. The referent group was females who had never received the HPV vaccine.

0.5-2.2
0.6-2.3
0.9-3.1

0.4-1.7
0.4-2.2
0.3-1.5
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Table 7
Univariate logistic regression model four
OR
95% CI
Provider asked about opinion/beliefs
None of the time
1.0
Some of the time
1.2
0.6-2.3
Most of the time
0.9
0.5-1.8
Always
0.8
0.4-1.5
Treated with respect by a medical provider
Some or none of the time
1.0
Most of the time
0.9
0.3-2.5
Always
0.6
0.2-1.6
Physician shares culture
None or some of the time
1.0
Most of the time
0.7
0.3-1.4
Always
0.9
0.5-1.8
Physician provides information that is easy to understand
Some or none of the time
1.0
Most of the time
1.1
0.5-2.4
Always
0.8
0.4-1.6
Satisfied with health care
Dissatisfied
1.0
Somewhat satisfied
0.9
0.3-2.3
Very satisfied
0.9
0.4-2.3
Note. The referent group was females who never received the HPV vaccine compared to females
who received the HPV vaccine between 17-26 years of age. Physician shares culture none or
some of the time was condensed due to increase cell size.
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Discussion
The current study revealed that just over half of the sample had initiated the HPV
vaccine, which is still far from the Healthy People 2020 goal of 80% coverage (Office of Disease
Promotion and Health Promotion, 2014). Encouragingly, of those who initiated the HPV vaccine
(and who reported the age in which they received the vaccine), the majority did so before the
national average age of sexual debut. Therefore, it is likely that many of these females were
protected against oncogenic serotypes of HPV before becoming sexually active. Nearly onequarter of the sample received no health care from an OBGYN or a GP in the previous year.
Although the lack of preventative care may be alarming, it is consistent with previous literature
which indicated this age group is generally less likely to receive preventative or ambulatory care
(Rand & Goldstein, 2018).
A small percentage of the sample received CAM care in the previous 12 months.
According to the National Institutes of Complementary and Integrative Care, the use of this type
of care increases around 18 years of age. As the majority of our sample received the HPV
vaccine before age 16, they may have started using CAM after their parents decided for them to
receive the HPV vaccine. Due to cell size prohibiting the inclusion of this variable in the
multinomial regression, we cannot determine if using this type of care is associated with
receiving the HPV vaccine in later adolescents/young adulthood specifically. In the future, it
may be more important to examine the parental use of CAM and their children’s HPV vaccine
coverage. Considering the vaccine-hesitant culture of these providers (Caulfield et al., 2017) and
the limited cell size in this study, continued research into CAM users’ health care behaviors,
particularly behaviors which impact the population’s health, such as vaccines, may be warranted.
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In the univariate logistic regression, respondents who received care from a GP only or a
GP and an OBGYN had higher odds of HPV vaccine uptake compared to respondents who did
not receive any health care. However, seeing an OBGYN was not associated with increased odds
of HPV vaccine reception. This sample’s GPs may be more likely to have recommended the
HPV vaccine than their OBGYNs. However, this would be contrary to previous work in which
researchers examined a nationally representative sample of primary care providers and reported
OBGYNS had higher odds of always recommending the HPV vaccine to patients aged 11-26
years compared to family practitioners (Malo et al., 2014; Vadaparampil et al., 2011).
Alternatively, it is possible that this sample was visiting their OBGYN for “problem visits”
rather than routine annual care and thus, the HPV vaccine may not have been the focus or reason
for the appointment.
In the multinomial logistic regression model, it again was revealed that visiting an
OBGYN only in the past 12 months was not related to HPV vaccine reception. However,
receiving care from a GP only or receiving care from a GP and an OBGYN revealed a 2.0 and
2.9, respective increase in the odds of receiving the HPV vaccine between 9-16 years of age
compared to respondents who did not receive care from either a GP or an OBGYN. Neither
receiving care from a GP nor an OBGYN in the previous 12 months was associated with
receiving the HPV vaccine between 17-26 years of age. The odds ratios were reduced when the
respondents who received the vaccine at a later age (17-26 years) were included in the analyses
(model 1); thus, reducing the apparent importance of seeing a GP. This suggests it is important to
stratify by the age of vaccine reception when examining factors associated with HPV vaccine
uptake.
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Furthermore, the multinomial model revealed a potential pattern of receiving health care
as recommended that starts at a younger age and continues into young adulthood; however,
longitudinal data are needed to confirm this. Previously, scholars have hypothesized that
forgoing preventative health care as a child can be harmful later in life by leaving them
vulnerable to preventable diseases and instilling a belief that preventative care is unimportant or
unnecessary (Cohen et al., 2010). Targeting the parents of young adolescents to take their
children to receive routine preventative health care may normalize the reception of health care,
which could lead to the continuation of this behavior into young adulthood.
Nearly 75% of the sample was not too worried or not at all worried about the cost of
routine health care. Most of the respondents, based on age, were eligible to receive insurance
coverage on their parent’s plans due to policies embedded in the Affordable Care Act (ACA)
(Patient Protection and Affordable Care Act, 2010). Furthermore, the ACA extended coverage
for preventative care, which would include vaccines, and may have contributed to this finding.
Regarding HPV vaccine uptake specifically, the odds of HPV vaccine uptake were not higher in
respondents who were not worried about the cost of routine health care. This finding may, in
part, be due to the extensions to preventative health care under the ACA, which required
insurance companies to cover the cost of the HPV vaccine, and the Vaccines for Children
program covers the cost of the HPV vaccine for many of the uninsured children/adolescents
(Center for Disease Control and Prevention, 2016; Patient Protection and Affordable Care Act,
2010). In the past few years, there have been proposed changes to the ACA that would reduce
coverage for vaccines (Dyer, 2017), and therefore, may have consequences for individuals who
are concerned about the cost of routine health care and their vaccine uptake.
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None of the variables in predictor variable set two, related to the patient-provider
relationship, were associated with the uptake of the HPV vaccine. Despite this finding, we do not
want to disregard the potential importance of these variables. This study was cross-sectional and
respondents might have switched health care providers between the time they received the HPV
vaccine and when they completed the NHIS survey. That would result in respondents providing
information about their current patient-provider relationship but having accepted the HPV
vaccine from a previous physician or when they were a minor and the decision was made by
their parents. Future research could inquire about these same variables with participants at the
event-level, such as surveying patients recently after the point of care. Alternatively, preexisting
beliefs and values, such as attitude toward vaccines or religious beliefs, may be more influential
contributors and will drive their decision to receive the HPV vaccine irrespective of their
relationship with their medical provider. This could be an area deserving of future research.
The strengths of this study include a nationally representative sample. Additionally, this
study moved beyond examining factors associated with receiving the HPV vaccine as a yes or no
variable by differentiating between receiving the HPV vaccine before or after the national
average age of sexual debut. Examining when individuals receive the HPV vaccine is important
because the recommendation is for adolescents to receive the HPV vaccine before sexual debut.
Another strength of this study was the inclusion of variables that are theorized to be relevant to
patient’s adherence to physician’s recommendations but have limited representation in the HPV
vaccine coverage literature. Limitations of this study include that it was cross-sectional in design
and for some respondents referred to a behavior that occurred when the participant was a minor
and thus the decision to get vaccinated might not have been in their control. Finally, the sample
adult panel from the NHIS was used, which does not include a measure of health insurance
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status. Future research could use the participant’s actual age of sexual debut. Additionally, future
research should include males.
Although the cross-sectional nature of this study precludes any causative statement, there
appears to be a pattern between receiving the HPV vaccine at a younger age and receiving
continued preventative care during young adulthood. Therefore, establishing behaviors of
receiving annual and preventative care during one’s formative years is important. In this crosssectional study, HPV vaccine uptake was not associated with characteristics of patient-provider
interactions.
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Abstract
In the past two decades cancer was acknowledged as a new health concern for individuals with
an intellectual disability (ID). Despite such recognition, no research in the US has sought to
examine their uptake of the cancer-preventing, HPV vaccine. Physicians can provide insight into
the factors they consider when deciding whether to recommend the vaccine and can provide
insight into the discussions they have with patients/caregivers regarding the vaccine. The
purpose of this study was to examine physicians’ experiences of recommending the HPV vaccine
to females with an ID. An online open-ended survey was employed. Data were analyzed using
inductive content analysis. Forty-nine out of 51 participants had previously recommended the
HPV vaccine to females with an ID. Physicians believed the HPV vaccine was important
because of the population’s noncompliance with pap smears and high risk of sexual abuse.
Physicians believed the vaccine was less important for patients who were unlikely to be sexually
active. Physicians generally described parents as uncertain, but receptive of the vaccine. There
were some responses which implied caregivers did not believe their child would be sexually
active and therefore were not at risk for contracting HPV. Both patients and parents believed
immunizations generally could be traumatic for this population. By and large physicians were
supportive of the HPV vaccine for females with an ID and perceived parents as wanting to
protect their child, but uncertain about the vaccine’s necessity. Further research is needed to
better understand this population’s gynecological health care needs.
Keywords: HPV vaccine, health care providers, cancer prevention,
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From 1970-2000 people with an intellectual disability (ID) were deinstitutionalized
(Metzel & Walker, 2001). With their integration into mainstream society, the life expectancy of
people with ID increased and consequently, diseases often associated with advanced age, such as
cancer, began to be diagnosed at similar rates as the general population (Hosking et al., 2016;
Sullivan et al., 2004; Walker, 2015). Secondary preventative behaviors for the detection of
cancer, such as pap smears, are invasive and can be challenging to perform in this population,
which has resulted in low uptake of this behavior (Greenwood & Wilkinson, 2013; Kavoussi et
al., 2009; Rivera Drew & Short, 2010). This makes primary prevention, such as the HPV
vaccination, even more important.
Within ten years of the HPV vaccine’s approval by the FDA, researchers found that there
was little known information about the acceptability and uptake of the vaccine in people with ID
(MacLeod & Tuffrey, 2014). To date, there remains no research on this topic that is exclusive to
the United States (US). Although no published research has been conducted in this area, an
unpublished preliminary query of data from the National Health Interview Survey (NHIS)
completed before the initiation of the current report, found the cell size for women with an ID
who received the HPV vaccine to be too low to conduct inferential statistics (National Center for
Health Statistics, 2008).
There are a few possible factors that may lead to a deficient uptake of the HPV vaccine in
this population. Parents and caregivers; hereafter referred to as "caregivers," with a child who
has an ID, sometimes have a misconception about their child's potential to engage in dyadic
sexual activity and consequently fail to recognize the risk of sexually transmitted infections
(STI) (Ballan, 2012; Rehm et al., 2012). Females with an ID do engage in dyadic sexual activity,
and they have a higher risk of being sexual assaulted compared to their typically-developing
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counterparts (Basile et al., 2016; Bernert & Ogletree, 2013; Hughes et al., 2012; Milligan &
Neufeldt, 2001; Rurangirwa et al., 2006). As such, they are subject to the unwanted
consequences of sexual activity, such as an HPV infection. Not recognizing these females as
capable of being sexually active may lead to their eschewing of primary preventative measures
related to sexual health, such as the HPV vaccine.
Furthermore, physicians play a vital role in HPV vaccine uptake (Rosenthal et al., 2011).
Physicians often make their HPV vaccine recommendations based on their estimation of the
patient’s engagement or potential engagement in sexual activity and are less likely to recommend
the vaccine if they believe the patient is not or will not become sexually active (Kepka et al.,
2012; Perkins et al., 2014). Although no research has specifically attempted to evaluate whether
physicians view females with an ID asexual, a narrative review of the topic concluded that
females with an ID are often inaccurately viewed as asexual, suggesting, physicians may hold
similar views (Milligan & Neufeldt, 2001). Lastly, despite recommendations that physicians
assume patients with an ID are at risk for STIs (Kripke, 2018), scholars theorize that physicians
experience barriers in providing general health care to individuals with an ID and that those
barriers are intensified when the patient has sexual health needs (Greenwood & Wilkinson,
2013).
Physicians with experience treating females with an ID are uniquely positioned to help
elucidate multiple factors that may impact HPV vaccine uptake in this population. For example,
physicians can provide insight into the factors they consider when deciding whether to
recommend the vaccine. Moreover, they can provide direct insight into the discussions they have
with patients and their caregivers regarding the HPV vaccine. As such, physicians can elaborate
on not only their perspectives about the HPV vaccine in this population but can also provide their

108

perceptions regarding caregivers' and patients' feelings towards the HPV vaccine. The purpose of
this study was to examine physicians’ thoughts regarding and experience of recommending the
HPV vaccine in females with an ID.
Method
The Institutional Review Board approved this study before data collection commenced.
An open-ended, cross-sectional online survey using Qualtrics Survey Panels was employed.
Inclusion criteria included: the completion of a medical residency in either pediatrics, obstetrics
and gynecology, or family medicine, practicing medicine in the US, being at least 26 years of
age, and previous experience caring for female patients with an ID. Potential participants were
provided with the definition of an intellectual disability from the American Association on
Intellectual and Developmental Disabilities. Exclusion criteria included identifying as anything
other than a pediatrician, OBGYN, or family practitioner (e.g., a pediatric cardiologist).
Protocol
Participants first completed a demographics survey. Next, participants answered a series
of open-ended questions. The open-ended questions were pilot tested before data collection to
ensure accurate interpretation of the question. Participants were asked if they ever have
recommended the HPV vaccine to their female patients with and without an ID, which was used
to route them to one of two series of questions.
Participants who had recommended the HPV vaccine to females with an ID received the
following questions:
1. What factors do you consider when deciding about whether to recommend the HPV
vaccine to female patients with an intellectual disability?
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2. Could you describe common responses from female patients with an intellectual
disability and their caregivers that you have encountered while recommending the HPV
vaccine to them?
a.

What were the patient's, parent's, or caregiver's questions?

b. What were the patient’s parent’s or caregiver’s comments, concerns, or emotional
responses?
Participants who had never recommended the HPV vaccine to a female patient with an ID
received the following questions:
3. What factors do you consider when deciding/choosing not to recommend the HPV
vaccine to female patients with an intellectual disability?
4. Have previous experiences discussing matters of sexual health or recommending the
HPV vaccine led you to not recommend the HPV vaccine to female patients with an
intellectual disability? This question was answered with “yes” or “no.” If “yes” was
selected, then participants would have been asked to elaborate on those experiences;
however, “yes” was never chosen.
All participants received the following questions:
5. What level of importance do you give the HPV vaccine in females with an ID
(unimportant, not very important, important, very important)? Which was followed up
with an open-ended question, why do you give it that level of importance?
6. Do you feel an obligation to convince female patients with an ID or their
parents/caregivers to consent to receive the vaccine (close-ended)? Do you believe you
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can effectively convince female patients with an ID or their parents/caregivers to consent
to their child receiving the HPV vaccine?
a. Why or why not?
b. What strategies have you used to be successful at receiving their consent?
Data Analysis
Data were analyzed through an inductive process using content analysis. This coding
method is commonly used when trying to understand health care professionals’ experiences
(Vaismoradi et al., 2013). The procedure for developing themes was guided by Perkins & Clark
(2013) and Elo and Colleagues (2014) (Elo et al., 2014; Perkins & Clark, 2013). The procedures
to prepare the data for multiple coders and obtain interrater reliability of the themes was guided
by Marcantonio & Jozkowski (2020) (Marcantonio & Jozkowski, 2020). Each open-ended
question was entered into Quirkos software separately and was analyzed independently from the
other questions. First, the lead researcher familiarized themselves with the data from each
question. Next, the lead author identified themes that emerged from each question. Initial themes
were condensed where appropriate and subthemes were formed from broader themes. When
necessary, themes were revised as needed. The second researcher then reviewed the codes and
themes and made appropriate adjustments. Finally, a codebook was developed. The codebook
was broken down by each question, theme, and subtheme. Two of three trained research
assistants were assigned to each question. Research assistants were instructed to code each
question independently of the other questions. Interrater reliability was run in SPSS version 26
and ranged between Cohen’s Kappa=.82-.93, with an average for the entire dataset of Cohen’s
Kappa=.91, which is good (Braun & Clarke, 2012).
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When a participant gave multiple responses to a single question, their response was
broken up thematically into multiple responses. Therefore, an individual’s data might be
represented multiple times in each question to reflect their entire response. For example, if a
participant said, “I think the HPV vaccine is important for females with an ID because they have
a risk high of being sexually assaulted and because they do not understand the consequences of
sexual activity” then that statement was broken down into two parts 1) risk of sexual assault and
2) not understanding the consequences. The sample size for each question refers to the number of
participants that provided a comprehensible response to that specific question, and responses
refer to the number of themes provided. See Table 1 for the response rate per question. Only two
participants indicated they had never recommended the HPV vaccine to a female patient with ID;
therefore, their responses to questions three and four are presented verbatim without associated
themes.
Descriptive information such as age, gender, region of the country in which the physician
practices medicine, years practicing medicine, medical specialty, has the participant ever
recommended the HPV vaccine to females with/without an ID, perceived importance of the HPV
vaccine for females with an ID, and a sense of obligation to convince patients/caregivers to
consent to receive the HPV vaccine were analyzed using SPSS version 24.
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Table 1.
Summary of response counts for each question
Question Number of
Number of
Range of
Average
Total
Number participants who
participants
responses
number of
number of
were presented
who answered per
responses per responses
with this question this question
participants participant
1
49
48
1-12
2.2
105
2a
49
28
1-6
3.1
86
2b
49
33
1-5
1.6
54
3
2
2
See notes
4
2
2
See notes
5
51
47
1-3
1.5
71
6a
51
28
1
1
28
6b
51
38
1-3
1.3
48
Note. Questions three and four were analyzed separately and are presented together in the results.
Regarding question four, both participants who were presented with this question responded
“no” to the close-ended portion of that question and therefore were not presented with an openended follow-up question.
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Results
A total of 124 people completed the survey. Fifty-four participants were excluded
because they identified their medical specialty as something other than family medicine,
pediatrics, or obstetrics and gynecology, ten provided completely incomprehensible data, six did
not have experience treating female patients with an ID, two participants were too young, and
one did not practice medicine in the US, leaving a final sample of 51 participants.
The average age of participants was 46.6±11.5 (range 29-72) years, and 51% of the
sample identified as women. Most of the sample were family practitioners (n=33), followed by
pediatricians (n=10), and OBGYNs (n=8). Over half of the sample were white (n=31), Asian was
the second most common race/ethnicity (n=13), followed by Black/African American (n=4), and
other (n=3). Private practice physicians represented 62.7% of the participants. Nearly one-third
of the sample was from the Midwest region of the country, and another one-third were from the
South region of the country. Complete descriptive results are in Table 2.
Most of the participant’s workplaces did not have a policy that required patients, after a
certain age, to have the HPV vaccine before receiving care at that facility (84%, n=41), seven
participants (13.7%) worked at a place that did have that requirement, and three participants
(5.9%) were unsure if their workplace had such policy. None of the participants believed the
HPV vaccine was, “not very important” or “unimportant” for females with an ID, 17 participants
(33.3%) believed the vaccine was “important” for females with an ID, and 34 participants
(66.7%) believed the vaccine was “very important” for females with an ID. Thirty-seven
participants (72.5%) felt a sense of obligation to try to convince patients/caregivers to consent to
receive the HPV vaccine, and 14 participants (27.5%) did not feel such obligation. For the
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complete results of the closed-ended questions, see Table 3. A list of all themes that emerged
from each open-ended question is found in Table 4.
Key of physician characteristics (for quotes)
(1) Medical specialty
P
Pediatrician
OB
Obstetrician and gynecologist
FM
Family medicine practitioner
(2) Gender
M
Man
W
Woman
(3) Region of the country
MW
Midwest
S
South
NE
Northeast
W
West
(4) Age
Years

Question 1. The first theme that emerged was that the factors are the same for all
patients. These responses did not provide additional information outside of stating that they will
recommend the HPV vaccine to all patients who meet the indications. For example, “I
recommend it for all patients no matter what.” P, M, MW, 53. As age is an indication for
administering the HPV vaccine, “age” was a subtheme that arose from the first theme. Some
participants discussed using age as a criterion per the vaccine schedules, “Age-see if they fit [the]
criteria for receiving the vaccine ([if] younger [then I] will give).” FM, W, S, 30. Another
participant indicated they consider physiological markers, which could be associated with age,
“Age (menstruating?)” FM, M, W, 61. The second subtheme was contraindications or reasons not
to administer the vaccine, which would hypothetically not be unique to the ID population. For
example, one participant said, “That they don’t have any history of allergy to the vaccine or any
components of the vaccine” P, W, MW, 47.
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Cancer prevention and if cancer prevention is necessary was the second theme that
emerged. Some participants indicated that the prevention of cancer is vital for all females,
“Cervical cancer risk exists for all females.” P, M, NE, 72, while another physician indicated
there are circumstances in which they would consider cancer prevention to be inconsequential,
“if poor prognosis or patient at end of life, no” FM, W, S, 30. Within this second theme, three
subthemes surfaced. The first subtheme was, pap smears not being tolerated well in this
population, which appeared to motivate physicians to recommend the HPV vaccine, “I take into
account that they often poorly tolerate office exams like pap smears which would be more
reliable as cervical cancer screenings in patients who do tolerate exams.” OB, W, MW, 32. The
second subtheme was having family health history of cancer. One participant wrote, “Family
history of cancer (if strong family history of cancer, [I am] more inclined to offer)” FM, M, NE,
29. The third subtheme was the patient’s sexual activity, and participants indicated they would be
more inclined to recommend the HPV vaccine if they perceived the patient was previously or
would become sexually active, “Sexual activity – [I am] more likely to recommend if current
active or has the potential to be.” FM, M, S, 43. Additionally, physicians considered their risk of
being sexually abused, “risk of sexual abuse for a patient with intellectual disability” P, M, S, 50
as indicators for recommendation.
The third theme that emerged was the severity of the patient’s intellectual disability, but
the responses were ambiguous about whether the physicians were more likely to recommend to a
patient with a mild or severe disability. For example, two responses were, “What is the patients
intellectual capacity.” FM, W, S, 42, and “level of intellectual disability (mild, mod, or
severe)?” FM, M, W, 61, which do not specify whether they prioritized vaccinating those with
mild, moderate, or severe disabilities. The fourth theme that emerged was the ability to obtain
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informed consent. Participants emphasized the idea that the patient must be able to understand
the vaccine and provide their consent. Some of the responses mentioned the caregiver’s consent.
However, most of the responses focused on informed consent from the patient, “Ability to offer
informed consent (if [the] patient [is] able to understand [the] benefits of vaccine, [I am] more
likely to offer).” FM, M, NE, 29. Some participants indicated they look for verbal affirmation of
their patient’s understanding, “Whether they can understand the risks and benefits of the
procedure and express that understanding in their own words” FM, W, MW, 34.
Finally, the fifth theme was the patient’s living situation with an emphasis on whether the
patient lives alone or in a facility with caregivers or people similar in age. However, the
responses were unclear about how this impacts their recommendations. One participant eluded to
their concern about male caregivers, “Are there male caregivers present” FM, W, S, 42 was their
response.
Question 2a. The first theme was that the questions were the same from all
caregivers/patients. The responses in this theme provided no additional information outside of
stating there are no differences in the questions asked, for example, “Questions are similar to
those of other parents.” P, W, MW, 47. The second theme was about the vaccine’s side effects.
Most responses were regarding general side effects of the vaccine. However, a couple responses
demonstrated questions about unique potential side effects such as, “Is this vaccine going to
influence pts mental status?” FM, W, MW, 40, or “Does it affect birth control potency?” FM, W,
MW, 34. Two subthemes under the side effects theme emerged, the first was questions about the
pain of the injection and the second was questions about the vaccine’s safety or “whether the
vaccine is dangerous or not?” FM, M, NE, 37.
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The third theme was inquiring about why their child needs the vaccine. The responses in
this category were primarily questions regarding why the vaccine was necessary for their child.
Some participants specified that the caregivers did not understand why the vaccine was
necessary for their child specifically because the caregivers believed their child was unlikely to
be sexually active. For example, one participant reported that a caregiver asked, “Is there any
chance of HPV if she is never sexually active?” FM, M, NE, 37. However, not all
caregivers/patients knew that HPV is linked with sexual activity. Theme four was exclusively
about HPV or cancer, but not the vaccine, and one participant wrote the following, “Many ask
questions about how HPV is transmitted.” FM, W, MW, 30. Furthermore, it was common for
participants to report that patients/caregivers had questions about the prevalence of HPV or
cervical cancer.
The vaccine’s efficacy to prevent HPV and cancer was the fifth theme that emerged. For
example, one participant wrote that a caregiver asked, “Will it prevent all types of cervical
cancer?” FM, M, S, 39. The sixth theme was questions about the vaccine’s cost and if it would be
covered by their health insurance. Finally, the seventh theme was about the HPV vaccine
guidelines. Several of the responses in this theme were about the number of doses that were
required. Less frequently, were questions about whether the vaccine is required and the approved
age range for receiving the vaccine.
Question 2b. Most commonly, participants reported that caregivers had a positive or
receptive response to their HPV vaccine recommendation. The following two responses
demonstrate this theme, “I tend to see caregivers for females with ID more likely to accept the
HPV vaccine than those without ID,” P, W, S, 47 and “….but the emotional response is that they
want the best for their child.” P, M, W, 45. Another participant suggested that both the caregiver
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and patient respond to the recommendation and are receptive, “In general, both patient and
parents agree with vaccination.” P, M, S, 50. While positive/receptive responses were the most
common, unfavorable/nonreceptive responses emerged as the third most common response. For
example, one participant said caregivers/patients are, “upset because [of the] recommendation
given” FM, W, S, 30. Another participant said the connection between HPV and sexual activity
could be upsetting to caregivers. This physician said, “occasionally the discussion of sexual
activity would bring about a sadness” FM, M, NE, 37. However, not all unfavorable/nonreceptive
responses were emotional. There was another participant who said there are concerns about the
logistics of receiving the vaccine. This participant said, “Concern is the number of
immunizations that will need to be given as they can be fairly traumatizing for some of my
patients with disabilities” FM, M, S, 43.
The third theme that materialized was uncertainty from caregivers/patients about whether
the vaccine was necessary; for example, one participant wrote: “[They] don’t understand why
[they] need the vaccine.” FM, W, MW, 47. The fourth theme to emerge was excuses not to get
the vaccine, and there was a wide variety of excuses, as evidenced by the following quotes: “My
daughter is nonverbal” and “we will watch her carefully.” P, M, NE, 72, and fear that the HPV
vaccine would encourage sexual activity, “Parental concerns primarily consists of issue around
encouraging sexual activity if the patients feels that she is protected this infectious/sexually
transmitted disease.” OB, M, S, 65. A subtheme within the excuses to not get the vaccine theme
was, believing the female with ID would remain sexually inactive and therefore did not need the
vaccine. This subtheme was the second most common response. One participant said that
caregivers will say, “My daughter will never be in a sexual relationship,” P, M, NE, 72. Another
physician said,
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“Sometimes patients and their caregivers are agreeable, other times caregivers don't
believe it is appropriate as they do not believe the patient is at risk given [their] intellectual
disability. It seems that this is the same phenomena that we see with teenagers or elderly people;
society believes that they are not sexually active or shouldn’t be” FM, W, MW, 34.
Finally, the fifth theme that emerged was the caregiver's/patient's concerns about the cost and
health insurance coverage of the vaccine.
Questions 3 and 4. Both participants who had never recommended the HPV vaccine to a
female patient with an ID were family practitioners, men, and both indicated they had
recommended the HPV vaccine to a female patient without an ID. Factors they consider when
choosing not to recommend the HPV vaccine were, “Patients with severe disability [are] not
sexually active [and are] under close supervision by mother an aide” NE, 46 and “The degree of
disability and if she is accompanied by a caretaker, are they family?” S, 67. Both participants
said previous experiences discussing HPV or sexual health did not influence their decision to not
recommend the HPV vaccine to their female patients with an ID. Despite their lack of HPV
vaccine recommendations, both participants indicated they believed the HPV vaccine was
“important” for this population.
Question 5. Seven themes and subthemes emerged as reasons why the vaccine was either
“important” or “very important” for females with an ID. Commonly participants responded that
it is important for females with an ID for the same reasons it is important for everyone else.
Responses in this theme did not elaborate beyond stating it was important for everyone. For
example, responses in this category were, “I think its important for all people to consider. I don’t
know if we have enough information yet to consider vital.” OB, W, NE, 43, and “The HPV
vaccine is important for all people to receive, regardless of gender or intellectual ability” FM, M,
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NE, 36. There was one subtheme to emerge out of the first theme and was the most common
response. This subtheme was the prevention of HPV and associated cancers. Examples of
responses from this theme were, “The HPV vaccine provides a level of protection, as some
patients may not get screened for cervical cancer.” OB, W, S, 39, and “want to lower their risk of
abnormal PAP smears/cancer” FM, M, MW, 65.
The second theme that emerged was that the importance of the HPV vaccine is dependent
on the patient’s potential to be sexually active. For example, one participant said, “It is important
but [the] greatest risk factor for HPV transmission is sexual activity, and some of my patients
with ID will never be sexually active.” FM, W, MW, 30. Another participant wrote, “I think its
less important if patients are not or will not be sexually active. This balances the higher
recommendation I give those who are or will be sexually active” FM, M, S, 43.
The third theme in this question was that the HPV vaccine is more important for females
with ID. Responses were only coded to this category if their response only stated that and
provided no additional information, such as, “It is more important in this group as a preventative
measure.” FM, W, S, 46. The subthemes in this theme are responses that may explain why some
physicians believed the HPV vaccine was more important for this sample. The first subtheme
was that this sample has a high risk of being sexually abused. One participant noted, “For those
with ID, it may be slightly more important because they may be more likely to be taken
advantage of in a sexual way. They may look more mature than they are intellectually” P, M, S,
47. Another participant specified that their living situations might contribute to their risk of
sexual abuse, “Most of the time [the] patient lives in group home where [the]patient do not
consent for sexual relation, so [the] patient [is]more exposed to [the]possibility of contracting
HPV.” OB, W, NE, 50. The second subtheme that emerged was the potential for not
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understandings the risks associated with sexual activity. Here is how one participant described
their concern, “They may not comprehend safe sex measures and may even engage in risky
sexual behaviors without being aware of the consequences. They may also not report sexual
activity (both consensual and nonconsensual) to family or health care providers.” OB, W, S, 39.
Finally, the third subtheme was contextual factors associated with having an ID. These responses
were broad but included factors that are unique to the ID population. For example, this response
related to their potential for noncompliance with pap smears, “Because some of these patients
can’t have pap smear due to physical or emotional barriers. And also high stress situation. Better
to get a vaccine instead for prevention than putting the patient through such a situation such as
obtaining a pap smear.” FM, W, S, 30.
Question 6a. This question was open-ended but resulted in four categories. Out of the
participants who responded to this question, 50% (n=14) said yes, they could convince
caregivers/patients to accept the vaccine, 10.7% (n=3) said no, they could not convince
caregivers/patients to accept the vaccine. Some participants, 25% (n=7), said they sometimes
could convince caregivers/patients to accept the vaccine. For example, one participant wrote
their confidence to convince the patient/caregiver to accept the HPV vaccine is dependent on
their relationship with the family, “Usually, if I have a relationship with the patient and/or
family” FM, M, S, 67. Another participant suggested that some people are just not persuadable,
“Usually but some parents are very resistant to the vaccine.” P, M, MW, 53. Finally, there was a
subset (14.3%, n=4) of participants that indicated they did not believe it is was their role as a
physician to convince caregivers/patients to consent. These participants still chose to discuss the
HPV vaccine with their patients, but believed their role was to educate and inform rather than
convince. As one participant wrote, “I don’t think it is convincing as much as it is educating the
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patient and family. As a primary care provider, it is my role to educate all patients and allow
them to make informed decisions with me about their care.” FM, W, S, 42.
Question 6b. Largely, physicians cited the use of education to convince
patients/caregivers to accept the HPV vaccine. A few responses were vague regarding the topics
but included the methods of education. For example, “Providing to such individuals
handouts/articles recently published for the education value, need to be comprehensive [in] the
information provided.” FM, M, NE, 55. Moreover, in the general education category, a
participant described efforts to establish an alignment of care between the patient and
themselves, that participant said, “We simply have a discussion. Ive found the most important
factor in a person consenting to the vaccine is if I, the physician, talks to them about it. Figure
out the hesitation, validate it and discuss it. We are responsible for protecting our patients and
advocating.” FM, W, MW, 34.
The educational topics that stood out as subthemes of education were: HPV, the longterm benefits of preventing HPV, and details about the vaccine. Education about HPV, largely
included informing patients about the prevalence of HPV, “It is difficult to change their minds;
still review how common hpv is.” P, W, MW, 39. Education about the long-term benefits of
preventing HPV included any education about the link between HPV and cancer. For example, a
participant said they complete “Counseling on what hpv causes including cervical, vaginal,
vulvar, anal, and head and neck cancers” OB, W, MW, 33. Finally, education about the HPV
vaccine specifically was believed to be a successful strategy for increasing uptake. As one
participant explained, “Most of time [the] patient needs more information on the vaccine. After
you explain 99% of patients will accept [the] vaccine.” OB, W, NE, 50. Also part of educating
caregivers about the vaccine was explaining the indications of use, “I just explain the availability
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and indication for the HPV vaccine.” FM, M, MW, 65 and highlight the vaccine’s safety, “Inform
them that HPV vaccination is well studied, highly utilized and effective and has been present for
years with minimal adverse effects noted.” OB, W, S, 39.
The second theme that emerged as a strategy to increase uptake of the HPV vaccine was
encouraging vaccination before sexual debut. For example, “I explain to them that it’s better to
vaccinate before the patient becoming sexually active.” P, W, MW, 47. The third theme to
emerge was fear appeals. One of the fear appeals emphasized the harsh clinical course of cervical
cancer; they said, “I also discuss the long and painful course of cervical cancer” OB, W, MW,
33. Another fear appeal was to focus on the patient’s risk of sexual abuse, “I point out delicately
that 10% of females have a first sexual experience against their will” FM, M, NE, 72. The final
theme that emerged was the use of empathy or trying to relate to the patient. Two participants
described telling their patients that they would accept the vaccine if it were them, “I often say
that personally I am vaccinated and I would vaccinate my children.” FM, W, MW, 34.
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Table 2.
Participant demographic information
M ± SD (range)
Age (years)
46.6±11.5 (29-72)
Years practicing
17.6± 9.5 (5-46)
medicine

N (%)
Gender
Men

25 (49.0)

Women
26 (51.0)
Urbanicity
Suburban
25 (49.0)
Urban
19 (37.3)
Rural
7 (13.7)
Medical special
Pediatrics
10 (19.6)
Family medicine
33 (64.7)
OBGYN
8 (15.7)
Race/ethnicity
White
31 (60.8)
Black/African American
4 (7.8)
Asian
13 (25.5)
Other
3 (5.9)
Region of the country
West
9 (17.6)
Midwest
17 (33.3)
Northeast
9 (17.6)
South
16 (31.4)
Type of practice
Public
12 (12.3)
Private
32 (62.7)
Not-for-profit
11 (21.6)
Teaching
6 (11.8)
Type of care provided most often
Ambulatory
39 (76.4)
Acute
6 (11.8)
Long-term
6 (11.8)
Note. Type of practice exceeds 100% because physicians could choose all that apply to their
place of practice.
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Table 3.
Close-ended questions related to the HPV vaccine
N (%)
Place of employment has an HPV vaccine policy*
Yes
7 (13.7)
No
41 (80.4)
I am not sure
3 (5.9)
Has ever recommended the HPV vaccine
To female patients without an intellectual disability
50 (98.0)
To female patients with an intellectual disability
49 (96.1)
HPV vaccine importance in females with an ID
Very important
34 (66.7)
Important
17 (33.3)
Sense of obligation to convince parents to consent to the HPV vaccine
No
14 (27.5)
Yes
37 (72.5)
*Participants were asked in their place of employment has a policy that requires patients (after a
certain age) to have the HPV vaccine before receiving medical attention that their facility.
Participants could choose to say the HPV vaccine was not very important or unimportant for
females with an ID, but no participants chose those options.
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Table 4.
Themes and subthemes from each open-ended question
n (%)
Q1. Factors considered prior to HPV vaccine recommendation
Same as patients without an ID
Age
Contraindications
Cancer prevention and if it is necessary
Pap smears not well tolerated
Family health history
Sexual Activity
Severity of the patient’s intellectual disability
Ability to obtain informed consent
Patient’s living situation
Q2a. Questions parents have after recommendation
Questions are the same from all parents
Side effects
Pain of the injection
Vaccine’s safety
Inquiring about why their child needs the vaccine
Why the vaccine is needed if their child is never sexually active
Request information about HPV or cervical cancer
Vaccine efficacy
Cost/insurance coverage
HPV vaccine guidelines
Q2b. Responses from parent after recommendation
Positive/receptive response
Unfavorable/nonreceptive feelings toward the vaccine
Uncertain about its necessity
Excuses to not get it
Not sexually active
Concerns about cost/insurance coverage
Q5. Why the vaccine is important for females with an ID
The same as reasons for other patients
Prevention of HPV and cancer
Importance depends on potential to be sexually active
More important for females with an ID
High risk of sexual abuse
They do not understand the risks associated with sexual activity
Contextual factors associated with having an ID
Q6a. Physician feels they can convince patients to accept the vaccine
Yes
No
Sometimes
Does not try to convince

11 (10.5)
23 (22.0)
6 (5.7)
4 (3.8)
2 (1.9)
3 (2.9)
26 (24.8)
8 (7.6)
12 (11.4)
10 (9.5)
2 (2.3)
15 (17.4)
5 (5.8)
6 (7.0)
15 (17.4)
10 (11.6)
9 (10.5)
9 (10.5)
4 (4.7)
11 (12.8)
16 (29.6)
10 (18.5)
6 (11.1)
6 (11.1)
13 (24.1)
3 (5.6)
16 (22.5)
32 (45.1)
5 (7.0)
3 (4.2)
9 (12.7)
3 (4.2)
3 (4.2)
14 (50.0)
3 (10.7)
7 (25.0)
4 (14.3)
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Q6b. Physician’s strategies to convince patients to accept the vaccine
Education
Education about the long-term benefits
Education about the HPV vaccine
Education about HPV
Encouraging vaccination prior to sexual debut
Fear appeals
Empathy

15 (31.2)
7 (14.6)
10 (20.8)
3 (6.3)
4 (8.3)
6 (12.5)
3 (6.3)
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Discussion
By and large physicians in this study were supportive, endorse, and recommend the HPV
vaccine to their female patients with an ID. All the participants indicated the vaccine was
“important” or “very important” for females with an ID. Most of the clinics/hospitals the
participants worked in did not require patients to have the HPV vaccine as a prerequisite to be
seen by a physician. Not all physicians felt obligated to convince caregivers/patients to accept
the HPV vaccine; however, since 49 out of 51 participants had recommended the HPV vaccine to
a female patient with an ID, so we can assume the majority take some actions toward increasing
HPV vaccine uptake. Although cancer prevention was a common theme throughout the entire
study, the prevention of genital warts, another possible outcome of HPV (National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 2019), was never mentioned.
Physicians cited several topics on more than one question. For instance, noncompliance
with pap smears came up as something the physicians consider when making their HPV vaccine
recommendation (question one) and as a reason why physicians believe the HPV vaccine is
important (question five). The perception of females with an ID as sexually inactive also
permeated throughout questions one, 2a, 2b, and five, which means both physicians and
caregivers share this belief. Finally, the risk of being sexually abused was a reason why the HPV
vaccine is important (question five) and used a fear appeal (question 6b).
Some factors that physicians consider when recommending the HPV vaccine to females
with an ID are similar to what previous literature has identified in the general population.
Medical providers frequently use the patient's age to determine appropriate recommendations.
Age is an indication for receiving the vaccine; however, both in this study, and previous
research, medical providers did not consistently use age in alignment with the CDC guidelines

129

and FDA regulations (Daley et al., 2010; Kepka et al., 2012; Perkins et al., 2014). In this study,
one physician said they use age in conjunction with the patient’s menstrual cycle, suggesting the
patient’s sexual/reproductive development may influence their HPV vaccine recommendations.
This approach may be ill-advised because the average age of menarche for females with an ID is
13.25 years and the CDC recommends all 11-12-year-olds receive the vaccine and because of the
high prevalence of sexual abuse in children with an ID (Centers for Disease Control and
Prevention, 2018; Horner-Johnson & Drum, 2006; Knickmeyer et al., 2006).
Other similarities between the findings in this study and previous literature include the
use of the patient’s sexual activity as an indicator for recommending the HPV vaccine (Kepka et
al., 2012; Perkins et al., 2014). Broadly this is problematic because the HPV vaccine should be
administered before, not in response, sexual debut. Furthermore, based on the factors used to
make predictions about whether a female with an ID will become sexually active (i.e., the
severity of disability, verbal or nonverbal, living situation, and if male caregivers are present),
these predictions likely have a high margin of error. What is more, the physicians in this study
believed females with an ID have a high propensity for hiding their sexual activity from
caregivers. Therefore, caregivers may never become aware of their child’s sexual activity unless
a problem arises, which further warrants prophylactic protection from HPV.
Participants in this study reported several unique factors they consider before
recommending the HPV vaccine to their female patients with an ID. First, pap smear
noncompliance led to concerns about undetected cervical neoplasms, which makes the
prevention of HPV even more critical. Secondly, when examining questions one and three, it
appeared as if physicians believe living in a group home or having a nonfamily caretaker was a
risk factor for contracting HPV. Two explanations are postulated. First, living in a group home
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may increase their exposure to peers and multiple caretakers, which physicians might view as a
risk factor for sexual assault or as having more opportunities to engage in desired sexual activity.
Secondly, patients who need a caregiver or live in a group home may be more severely disabled
than patients who live independently and therefore are more vulnerable to sexual assault.
Finally, the ability to obtain informed consent was a consideration, presumably for legal
and ethical reasons. These responses emphasized the informed portion of consent, suggesting
that physicians had concerns about the patient’s decisional capacity. Informed consent involves
knowing the name of one’s condition, the name of the procedure or treatment and the associated
risks and benefits, and associated risks and benefits of not receiving treatment (Centers for
Medicare and Medicaid Services, 2007). The physicians queried patients for these consent cues.
For example, having the patient explain, in their own words, their understanding of the vaccine.
There were also similarities in medical providers’ descriptions of parental reactions to
their HPV vaccine recommendation between previous research and the current study. For
example, Perkins & Clark, (2013) revealed medical providers reported that parents, said their
child was too young, were concerned about the potential side effects and safety, and believed
their child would remain sexually inactive for several more years (Perkins & Clark, 2013).
Nevertheless, there were caregiver concerns specific to their child’s ID. One participant indicated
they received a question from a caregiver wondering if the vaccine would impact their child’s
mental capabilities. This line of inquiry from caregivers may be reminiscent of the now wholly
disproven claims of a potential link between autism and vaccines (Gerber & Offit, 2009; Jain et
al., 2015; Stehr-Green et al., 2003). Additionally, there was a shared understanding between
caregivers and physicians that immunizations are traumatic for patients with disabilities, which
may discourage caregivers/patients from accepting the vaccine.
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Physicians’ strategies to increase HPV vaccination in their female patients with an ID had
commonalities with previous research examining strategies used by medical providers treating
the general population. Previously, providers reported stressing HPV vaccination before sexual
debut, emphasizing cancer prevention, trying to relate to their patients through empathy or selfdisclosure, and reassuring patients that the vaccine is safe (Henninger et al., 2017; Perkins &
Clark, 2013). Physicians in this study reported the use of fear appeals, including messages of
potential sexual assault; which was also a message reported by the medical providers in previous
literature (Perkins & Clark, 2013). While fear appeals often do not have the desired outcomes
(Kok et al., 2018), one study discovered that HPV vaccination messaging, which has facets of
fear appeals, might be useful at increasing the acceptance of the HPV vaccine in some parents
(Malo et al., 2014). Future research could explore various types of HPV vaccination messaging
to determine if fear appeals are effective in this population.
Conclusions and Future Research
This study was the first in the US to examine attitudes toward and beliefs about the HPV
vaccine, specifically for females with an ID. Despite cancer being a newer health concern in
persons with an ID (Sullivan et al., 2004), physicians seemed to understand this emerging health
concern and value relevant preventative measures. Given the parallels between previous work
and the current study, we can tentatively conclude the clinical process of HPV vaccine uptake is
comparable between female patients with and without an ID. There were, however, several
peculiarities for females with an ID that may make the process of obtaining the HPV vaccine
slightly more complicated, which might contribute to insufficient uptake of the HPV vaccine in
this population. However, physicians in this study were highly supportive of the HPV vaccine,
and although some physicians described negative or uncertain responses from caregivers

132

following their HPV vaccination recommendation, nearly 1/3 of the responses were positive or
receptive. Thus, caregivers seem uncertain about their child’s risk of contracting HPV, but still
frequently support its administration.
There was little evidence in this study to explain the low the uptake of the HPV vaccine
in this population. Because the NHIS relies on self-reported data, which requires people know
and be able to identify aspects of their health status, it is possible individuals with an ID are
being misclassified, which could lead to poor surveillance of their health behaviors and health
statuses. More surveillance of this population’s HPV vaccine coverage in the US would help in
understanding their gynecological care needs.
Further research in this area is needed. Future studies could benefit from having a larger
sample size. For example, medical school and medical residencies are increasingly incorporating
lessons on patient communication into their curricula (Travaline et al., 2005), therefore with a
larger sample size, researchers compare approaches to discussing the HPV vaccine between
newer versus more experienced physicians. Additionally, with a larger sample of physicians,
comparisons between the region of the country, medical specialty, or gender could be conducted.
In-person interviews which would allow researchers to ask follow-up questions and for
clarification would provide additional insight. Future research should include males with an ID.
Finally, researchers could interview caregivers and persons with an ID as well.
Strengths and Limitations
The strengths of this study include obtaining perspectives from three different medical
specialties. Additionally, this study provided insight into both the physician’s thoughts about the
HPV vaccine in females with an ID and the caregiver’s reactions toward the HPV vaccine
recommendation (from the physician’s perspective). Finally, this study focused on a vulnerable
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population that has not yet received attention in the literature. Limitations of this study include a
small sample size. Furthermore, the online format of this study did not allow for the probing,
follow-up questions, and clarification. Finally, this study did not stipulate a specific type or
severity of their intellectual disability.
Funding: This study was supported, in part, by the Doug Kirby Adolescent Sexual Health
Research Grant from the Rural Center for AIDS/STD Prevention, Indiana University School of
Public Health-Bloomington.
Acknowledgements: The authors would like to thank Christian Marez, Meghan Bailey, and
Karen Kayijuka for the time and commitment to coding the data presented in this study.
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Final Conclusions
This dissertation sought to examine the HPV vaccine in females with an emphasis on the
role of the health care providers. This dissertation used both a secondary nationally
representative data to conduct an epidemiological investigation into health care use and
characteristics of the patient-provider relationship is association with the HPV vaccine uptake
and an open-ended survey of physicians. This dissertation extended the literature indicating that
receiving care from a physician is important for the HPV vaccine uptake.
It was revealed that visiting a general medical provider is important for the uptake of the
HPV vaccine. Females who received care from both a general medical provider and an OBGYN
had the highest odds of HPV vaccine uptake. However, just seeing an OBGYN, was not
associated with the uptake of the HPV vaccine. When the sample was divided into females who
received the HPV vaccine before the national average age of sexual debut and after the national
average age of sexual debut, there was no longer a significant association between seeing a
general medical provider and the uptake of the HPV vaccine in those who received the HPV
vaccine after the national average of sexual debut. However, the odds ratio of HPV vaccine
uptake for those who received the HPV vaccine before the national average age of sexual debut
was greater than the odds ratio when examining HPV vaccine uptake as a yes/no variable in
association with receiving care from a general medical provider. Thus, including females who
received the HPV vaccine later in life artificially reduced the apparent importance of seeing a
general medical provider in relation to receiving the HPV vaccine. Although the cross-sectional
nature of this study precludes any causative statement, there appears to be a pattern that develops
in those who receive the HPV vaccine in their formative years that leads to the continuation of
this behavior into young adulthood.
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None of the characteristics of the patient-provider relationship included in these analyses
were associated with the uptake of the HPV vaccine. It may be that these specific factors do not
influence female’s uptake of the HPV vaccine. Alternatively, in between the time they received
the HPV vaccine and the time they completed the NHIS survey, they may have switched
physicians. That would result in respondents providing information about their current patientprovider relationship but having accepted the HPV vaccine from a previous physician or when
they were a minor and the decision was made by their parents. Another possible explanation for
the lack of significant associations is that there are other, more influential factors, that effect a
patient’s decision to accept the HPV vaccine. For example, preexisting beliefs about vaccines in
general or religious beliefs may be the primary drivers of HPV vaccine uptake and irrespective
of their relationship with their medical provider, those factors will more influential on their HPV
vaccine acceptance.
In the open-ended portion of this dissertation it was learned that physicians are supportive
and endorse the HPV vaccine in females with an intellectual disability. Physicians believe the
HPV vaccine is important for females with an intellectual disability for many of the same
reasons it is important for everyone but also for a few additional reasons. For example, females
with an intellectual disability are often noncompliant with pap smears and have a risk of being
sexually abused. Furthermore, physicians were also concerned about this population’s living
situation and who their caretakers were, with an emphasis on whether the caretaker was a family
member or if the caretaker was a male or female.
Physicians report that parents/caregivers/patients were frequently supportive of the HPV
vaccine, yet unsure about their child’s risk. Parents were concerned about the side effects of the
vaccine and often ask physicians questions about the potential for such outcomes. Some parents
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had unique concerns such as the vaccine’s impact on mental capabilities or on the efficacy of
contraception. Parents and physicians had a shared belief that immunizations were traumatic for
persons with an ID.
Many, but not all, physicians feel an obligation to try to convince patients to accept the
HPV vaccine. Other physicians said it is not about convincing patients, but rather about
educating them to make the best decisions for themselves. Their confidence to be able to
convince parents to accept the vaccine varied as well. Some physicians did feel confident to do
so, others did not, and most indicated that they felt confident to convince patients some of the
time, but that it depends on the patient. Some of the tactics used to convince their patients to
accept the HPV vaccine included, education about the HPV vaccine, HPV, and the long-term
benefits of prevention HPV (i.e., cancer prevention). Some physicians restored to fear appeals to
increase acceptance, while other tried to relate to their patients through self-disclosure of
empathy.
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Appendix C
Dissertation M2 Codebook
Always ask Brooke before coding something that you find to be confusing.
Never discuss your codes with each other (Karen, Meghan, Christian)
If you have a question about the software, please just ask Brooke for help.
Risk, exposure, sexual activity, and indications are all ways of saying the participant may be
exposed to HPV.
Words like, long-term, future, cancer prevention should all be considered as the long-term
benefits of preventing HPV and thus benefits of the vaccine.
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Q2. YesRecFactors
This question asked, what factors do you consider prior to recommending the HPV
vaccine to females with an intellectual disability. Therefore, all responses are indicators that
physicians use to justify their recommendation
No Different Than People without a Disability.
Any statement that directly states or eludes to there being no differences in the factors
they consider prior to recommending the HPV vaccine for patients with or without an intellectual
disability. If any additional information is provided, consider another theme first.
Age (Subtheme).
Anything regarding the patient’s age.
Contraindications (Subtheme).
Is a situation or factor in which the vaccine cannot or should not be administered (except
for sexual inactivity).
Cancer Prevention and if it is Necessary.
If the statement directly states or eludes to their consideration of preventing cancer as a
reason to recommend the HPV vaccine, then it should be included here. Additionally, if it refers
to the necessity or lack thereof in this population. Furthermore, if the statement refers to the
long-term benefits or long-term consequences then it should also be included in cancer
prevention as cancer is the long-term consequence of HPV.
Pap Smears not Tolerated (Subtheme).
If the statement refers to pap smears not being easy or being difficult or impossible to
conduct.
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Family Health History (Subtheme).
Anything referring to family history or family’s cancer risk or preexisting cancer risk.
Sexual Activity.
If you think the response is referring to their sexual history, potential to become sexually
active, or risk of being abused then it should be coded here. As sexual activity is the risk or
exposure in which HPV is contracted, these should also be considered as sexual activity.
Severity of Intellectual Disability.
Anything that refers to the severity of their disability, type of disability, or their
intellectual capacity.
Ability to Obtain Informed Consent.
Informed consent requires the patient understand the purpose, risks, benefits of the
vaccine and agree to receive the vaccine. Alternatively, the parent or caregivers can support and
consent to the patient receiving the HPV vaccine. So, anything that impacts the ability of the
physician to obtain informed consent should be coded here.
Living Situation.
If anything is referring to where they live, who takes care of them, and who they interact
with on a regular basis.
Q3:QuestionsAfterHPVVReco
This question asked participants what questions patient’s, parent’s or caregiver’s have
after receiving a recommendation that the patient receive the HPV vaccine. Thus, physicians are
reporting on the questions they receive, not questions they ask AND you can assume each
statement was once asked in a question form.
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Questions are the Same from All Parents.
Statements that say there is no difference in the questions parents ask based on
characteristics of their child. If the response provides more information other than just stating all
questions are the same, consider another theme.
Side Effects.
Questions that refer to side effects of the vaccines or consequences as a result of having
been vaccinated.
Pain of Injection (Subtheme).
Questions that ask about pain, hurting, or discomfort the vaccine will cause.
Safety (Subtheme).
Questions that ask more specifically about the safety or danger of the vaccine.
Information about HPV or Cervical Cancer.
Questions about HPV or cervical cancer, but not questions about the vaccine.
Inquiring about Why Their Child Needs the Vaccine.
Generally requesting more information about why the vaccine was recommended for
their child
My child is Not Sexually Active, why do They Need it? (Subtheme).
Also requesting more information, but specifically because they believe their child is not
sexually active or that their child does not present themselves as being at-risk or exposed and
therefore are wondering why their child would need the vaccine
Vaccine Efficacy.
Efficacy is how well the vaccine does what it is supposed to do. The vaccine is supposed
to prevent HPV, which causes cancer. So how well does the vaccine do that.
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Cost/Health Insurance.
This refers to questions about how much the vaccine will cost or if their insurance will
cover the cost of the vaccine.
Guidelines for Receiving the Vaccine.
Any questions about requirements of the vaccine, recommendations for vaccine
reception, necessary number of doses, or regulations for receiving the vaccine. Think about CDC
and FDA guidelines for the vaccine.
Q4: ResponsesParentPatientAfterReco
This question asked participants, “What comments, concerns, emotional responses did
parents/caregivers or patients have after you recommended their female child with and ID
receive the HPV vaccine”
Positive/Receptive Response.
This refers to responses that suggest the parent/caregiver/patient accepted the vaccine
after the physician recommended it. This also refers to parents/caregivers/patients who had
positive attitudes, were grateful, happy, or understood the importance of receiving the vaccine.
Generally, this is anything that suggests the vaccine was accepted after recommendation or the
parent/caregiver/patient had positive feelings toward the recommendation/vaccine.
Unfavorable Feelings.
Anything that suggests that parents/caregivers/patients generally do/did not accept the
vaccine or experience negative emotions because of the recommendation. Alternatively, it could
that the recommendation to receive the HPV vaccine brings about negative feelings because it
forces the parent to consider their child as a sexual being.
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Uncertain About its Necessity.
This is not people who feel negatively or positively toward the vaccine, they just are not
sure that their child needs the vaccine and may trying to figure out if it is necessary for them to
receive it. These are not negative emotions, these are just people who are unsure about the
vaccine.
Excuses to Not Get the Vaccine.
Anything that implies a parent/caregiver/patient has a “reason” as to why their child does
not need the vaccine. This reason could be related to their disability or how they [the parents]
have other ways of preventing HPV and thus warranting the vaccine as unnecessary. Be very
clear about the differences between uncertain about its necessity and excuses not to get
it. Excuses not to get it are typically apparent final decisions.
They are not Sexually Active (Subtheme).
This implies the parent/caregiver/patient determines the vaccine is not necessary because
they will not be exposed to HPV
Concerns about Cost/Coverage.
This refers to responses that people might have regarding the cost or insurance coverage
of the HPV vaccine
Q5: WhyImportance
This was a follow up question. The first question was, “What level of importance to do
you give the HPV vaccine in females with an intellectual disability?” Following that question,
participants were asked, why do you give the HPV vaccine that level of importance? This is the
question you are actually coding. In other words, why does the physician (participant) believe the
HPV is very important or important for females with and ID.
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The Same as People without ID.
This is any statement in which the physician says there is no difference in their perceived
importance in the uptake of the HPV vaccine between a female with ID and anyone else.
Preventative Behavior (Subtheme).
Any general statement that implies it is important because it can prevent HPV or cancer
Importance Depends on Current or Potential Sexual Activity.
Here you should code statements that imply the level of importance of the HPV vaccine
in females with an ID is dependent on their current sexual activity or potential to become
sexually active.
More Important for Women with ID.
Any general statement that states it is more important for females/women with an ID to
receive the HPV vaccine than it is for other to receive the HPV vaccine.
Risk for Sexual Abuse (Subtheme).
The HPV vaccine is important for females with an ID because of their risk for being a
victim of sexual abuse
Contextual Factors Associated with Disability (Subtheme).
The HPV vaccine is important for females with an ID because of the way their life is
different because of their disability, living situation, unique aspects of living with an intellectual
disability or how life is different due to their disability.
They Do Not Understand the Risks of Sexual Activity (Subtheme).
This is stating that the HPV vaccine is more important for women with an ID
because when they engage in sexual activity, they are often unaware of the associated risks with
being sexually active and therefore need to be protected from those risks in other
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ways. Additionally, because they do not understand the risks, they may be more likely to engage
in high-risk behaviors or unprotected sex.
Q6a: WhyCanCannotConvince
This question asked: Do you believe you can effectively convince parents or caregivers
or patients to consent to receiving the HPV vaccine? Why or why not?
Yes.
Must be an uncontested, non-context specific yes. Meaning if they respond by saying
“yes, if..” or “yes when..” then the yes is conditional and therefore should not be coded as an
absolute “yes” since their yes is dependent on a specific situation.
No.
Must be an uncontested, non-context specific no.
Sometimes.
Anything that refers to their belief that they can sometimes (not never and not always)
convince parents to consent to their child receiving the HPV vaccine. This is where “yes if” and
“yes when” should be coded because they believe they can convince when the situation meets
specific circumstances.
Does Not Try to Convince.
This is anything that refers to convincing as not being the physician’s goal, but rather
education or some other goal other than just convincing them to accept the vaccine.
Q6b StrategiesConvince
This question asked the following, what strategies have you used to get
parents/caregivers or patients to consent to receiving the HPV vaccine?
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Education.
This are responses that are broad and just include information that indicates
the physician provides and education or how or the methods they use to educate. If they provided
topics they educate about, consider one of the subthemes.
Educate About the Long-Term Benefits of Preventing HPV (Subtheme).
This is when physicians specifically try to educate about how preventing HPV can lead
to long-term health benefits, notably but not exclusively to cancer. These must be specific to
long-term benefits
Educate about HPV (Subtheme).
This is when physicians try to educate about the virus, HPV. This is not education
about the vaccine, but rather specifically education related to HPV
Educate about the HPV Vaccine (Subtheme).
This is when physicians try to education about the vaccine specifically. This could
be about the guidelines, requirements, efficacy.
Encourage Vaccination Prior to Sexual Debut.
This is when physicians try to focus on why vaccinating younger or before first sex is
beneficial to the female with ID.
Fear Appeals.
If the physician states that they use a tactic in which appears to be trying to scare
parents/caregivers/patients into accepting the vaccine, then this is considered a fear appeal.
Often, but not always, this moves beyond general education about the benefits of the vaccine and
instead focuses perils or worst-case scenario or a potential negative situation in which is out of
their [the parents] control. Often time fear appeals can appear subtle but really, they are intended
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scare people into a behavior. For example, instead of saying I tell them the vaccine can prevent
cancer, a fear appeal might say, I tell them how terrible cancer is.
Empathy.
The definition of empathy is, the ability to understand and share the feelings of
another. Any time the physician is trying to relate to the patient, the code should be identified as
empathy.
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